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ABSTRACT 
Angiogenesis, the growth of new microvasculature from pre-existing blood vessels, is essential 
for tumor growth and metastasis in several cancers, including breast cancer. The vascular endothelial 
growth factor (VEGF) is the primary signaling molecule promoting angiogenesis. As such, the VEGF 
signaling axis is a potential target to inhibit tumor angiogenesis. However, full tumor vascular inhibition 
has yet to be achieved, attributed to the complexity of the vascular environment. Conversely, the ability to 
induce angiogenesis to vascularize ischemic tissue would provide treatment options for vascular diseases, 
including peripheral artery disease and coronary artery disease. Hemodynamic forces drive vascular 
disease progression, and contribute to the induction and directionality of vessel growth. Thus, full 
vascular control can be obtained by targeting VEGF signaling to inhibit angiogenesis and by targeting 
hemodynamic forces to promote angiogenesis. To this end, I developed computational approaches to 
individually understand the effects of VEGF signaling and hemodynamic forces on angiogenesis. 
Firstly, VEGF signaling models enable anti-angiogenic treatment efficacy to be correlated to 
features of cells or the microenvironment, which can help us understand a major challenge in tumor 
vascular inhibition: tumor heterogeneity. Indeed, cell population heterogeneity has been identified as an 
important consideration in cellular response to VEGF treatment, and is also a major factor in angiogenic 
drug resistances. However, there are few techniques available to represent and explore how heterogeneity 
is linked to population response. Recent high-throughput genomic, proteomic, and cellomic approaches 
offer opportunities for profiling heterogeneity on several scales. We have recently examined 
heterogeneity in VEGFR membrane localization in endothelial cells. We and others processed the 
heterogeneous data through ensemble averaging and integrated the data into computational models of 
anti-angiogenic drug effects in breast cancer. Here we show that additional modeling insight can be 
gained when cellular heterogeneity is considered. We present comprehensive statistical and computational 
methods for analyzing cellomic data sets and integrating them into deterministic models. We present a 
novel method for optimizing the fit of statistical distributions to heterogeneous data sets to preserve 
important data and exclude outliers. We compare methods of representing heterogeneous data and show 
methodology can affect model predictions up to 3.9-fold. We find that VEGF levels, a target for tuning 
angiogenesis, are more sensitive to VEGFR1 cell surface levels than VEGFR2; updating VEGFR1 levels 
in the tumor model gave a 64% change in free VEGF levels in the blood compartment, whereas updating 
VEGFR2 levels gave a 17% change. Furthermore, we find that subpopulations of tumor cells and tumor 
endothelial cells (tEC) expressing high levels of VEGFR (> 35,000 VEGFR/cell) negate anti-VEGF 
treatments. We show that lowering the VEGFR membrane insertion rate for these subpopulations 
recovers the anti-angiogenic effect of anti-VEGF treatment, revealing new treatment targets for specific 
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tumor cell subpopulations. This novel method of characterizing heterogeneous distributions shows for the 
first time how different representations of the same data set lead to different predictions of drug efficacy.  
Secondly, to understand how to better promote angiogenesis, accurate quantification of 
hemodynamic forces is essential. Numerical simulations allow for this quantification. However, due to the 
complexity of numerical simulations, blood is often assumed to be Newtonian, despite being non-
Newtonian in nature. To ensure accurate representation of hemodynamic forces, we compare 
hemodynamics between Newtonian and non-Newtonian models of blood. We test these models in both 
healthy and atherosclerotic arteries. For the non-Newtonian model, we employ a shear-rate dependent 
fluid (SDF) constitutive model, based on the works by Yasuda et al in 1981. We first verify our stabilized 
finite element numerical method with the benchmark lid-driven cavity flow problem. Numerical 
simulations show that the Newtonian model gives similar velocity profiles in the 2-dimensional cavity 
given different height and width dimensions, given the same Reynolds number. Conversely, the SDF 
model gave dissimilar velocity profiles, differing from the Newtonian velocity profiles by up to 25% in 
velocity magnitudes. This difference can affect estimation in platelet distribution within blood vessels or 
magnetic nanoparticle delivery. Wall shear stress (WSS) is an important quantity involved in vascular 
remodeling through integrin and adhesion molecule mechanotransduction. The SDF model gave a 7.3-
fold greater WSS than the Newtonian model at the top of the 3-dimensional cavity. The SDF model gave 
a 37.7-fold greater WSS than the Newtonian model at artery walls located immediately after bifurcations 
in the idealized femoral artery tree. The pressure drop across arteries reveals arterial sections highly 
resistive to flow which correlates with stenosis formation. Numerical simulations give the pressure drop 
across the idealized femoral artery tree with the SDF model which is approximately 2.3-fold higher than 
with the Newtonian model. In atherosclerotic lesion models, the SDF model gives over 1 Pa higher WSS 
than the Newtonian model, a difference correlated with over twice as many adherent monocytes to 
endothelial cells from the Newtonian model compared to the SDF model. 
Together, these computational approaches provide a necessary step towards obtaining full 
vascular control, through inhibiting or promoting angiogenesis, respectively.  
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CHAPTER 1 
QUANTITATIVE CHARACTERIZATION OF CELLULAR MEMBRANE-RECEPTOR 
HETEROGENEITY THROUGH STATISTICAL AND COMPUTATIONAL MODELING1 
1.1 Introduction 
 Drug resistance is one of the largest challenges in providing effective cancer treatment, and 
cellular heterogeneity is a main component of drug resistance [1]. Cellular heterogeneity can regulate 
systemic response, and mapping these heterogeneities is a grand challenge in biomedical research 
[2]. Heterogeneity also represents a challenge in the emerging field of personalized medicine since 
variability in patient populations can result in differential therapeutic outcomes [3]. Recent analyses 
of breast cancer cell lines and xenografts on the genetic and proteomic levels have offered significant 
insight into tumor heterogeneity [4, 5]. Similarly, genetic screens of patient tumor samples have 
highlighted the challenge of tumor heterogeneity in both personalized medicine and biomarker 
development [6]. Understanding how to characterize cellular heterogeneity will help surmount drug 
resistance challenges and develop more effective cancer treatment approaches.   
Recent efforts to characterize heterogeneity have applied optical biosensors [7-9]. We have 
recently optimized conditions for phycoerythrin (PE)-antibody based labeling and profiling the 
vascular endothelial growth factor receptors (VEGFR) on endothelial cells, in vitro [10] and ex vivo  
[11-13], with fluorescence calibration to commercially available PE beads [14, 15]. These data  
 
1This work has been previously published by the degree candidate. 
Citation information: Weddell JC, Imoukhuede PI (2014) Quantitative Characterization of Cellular 
Membrane-Receptor Heterogeneity through Statistical and Computational Modeling. PLoS ONE 9(5): 
e97271. doi:10.1371/journal.pone.0097271 
Copyright: © 2014 Weddell; Imoukhuede. This is an open-access article distributed under the terms of the 
Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in 
any medium, provided the original author and source are credited. 
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showed significant cell-by-cell variation in surface receptor levels across similar cell populations. We 
have also developed new quantum dot beads for quantitative calibration of heterogeneity [16]. The 
development of these tools to characterize heterogeneity has resulted in a need for better data 
analysis and model incorporation methods.   
Defining standards for statistically characterizing heterogeneous data often requires 
presuppositions on the type of statistical distribution. In analyzing flow cytometry data, 
Boedigheimer and Ferbas automated data gating (selection). Using expectation maximization, they 
modeled the data as a mixture of Gaussian distributions [17]. Various commercial software 
automatically gate with a predefined bivariate normal or t-distributions [18]. However, analyzing 
heterogeneous data with such presuppositions could neglect essential features. As such, methods for 
statistically characterizing heterogeneous data with no predisposition on the data distribution are 
needed. 
 Systems biology offers useful approaches for gaining both data-driven and in silico insight 
into heterogeneous biological systems. In particular, in silico models have applied sensitivity analysis 
to probe population outliers as a proxy for heterogeneity: Schoeberl et al showed that increasing the 
number of epidermal growth factor receptors (EGFR) ten-fold in the presence of external epidermal 
growth factor (EGF) resulted in approximately a 3-fold decrease of the amount of extracellular 
signal-regulated kinase (ERK) phosphorylated downstream the signal transduction pathway within 
one hour [19]. Saterbak et al showed that heterogeneity in membrane receptors-cell adherence 
significantly alters cell detachment kinetics to an applied shear force [20]. While these and other 
computational models have shown the importance to account for receptor heterogeneity, well defined 
methods have not been developed for integrating experimental heterogeneity into deterministic 
models.   
 In this study, we present comprehensive statistical and computational methods for analyzing 
cellomic data sets and integrating them into deterministic models. Here we show that fitting protein 
3 
 
data to statistical distributions provides useful parameters for describing cellular populations. We 
show how these various cellular population representations affect the vascular endothelial growth 
factor (VEGF) distribution throughout a whole-body model, anti-VEGF treatment efficacy, and how 
these representations may affect anti-VEGF treatment at different time points during tumor growth. 
Additionally, we mathematically describe the necessity to target treatment techniques to tumor cell 
subpopulations. 
 
1.2 Materials and Methods 
Experimental receptor data. VEGFR1, -R2, -R3, and neuropilin-1 (NRP1) levels were 
quantified on human umbilical vein endothelial cells (HUVEC) acquired from individual donors 
(Lonza, Walkersville, MD and Stem Cell Technologies, Vancouver, Canada), as previously 
described [10]. VEGFR1 and -R2 levels were quantified on primary mouse endothelial cells, which 
were freshly isolated from gastrocnemius and tibialis anterior of male and female 8-14 week old 
C57BL/6 (Charles River and NCI) and BALB/c (NCI) mice, as previously described [11]. VEGFR1 
and -R2 were quantified on tumor endothelial cells and tumor cells obtained from MDA-MB-231 
xenograft studies, as previously described [13]. These MDA-MB-231 cells were kindly provided by 
Dr. Zaver M. Bhujwalla (Johns Hopkins University) with the following details about the cell line: 
MDA-MB-231 breast cancer cells are purchased from the American Type Culture Collection 
(ATCC) and used within 6 months of obtaining them from ATCC; the cell line is tested and 
authenticated by ATCC by two independent methods; the ATCC cytochrome C oxidase I PCR assay 
and short tandem repeat profiling using multiplex PCR, this is as previously described [13]. No 
experimental data was acquired in this study. Ethics committee approval for data used here can be 
found in our previous publications [10, 11, 13]. 
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 Computational Models. The Popel laboratory has developed a whole-body VEGF kinetic and 
transport model necessary for building VEGF-mediated angiogenesis models [21, 22]. We and others 
recently advanced this model to include experimentally quantified VEGFR levels on tissue, to 
explore the pharmacokinetics and pharmacodynamics associated with an anti-VEGF drug (Fig. 1.1), 
and how this drug influences systemic, tissue, and tumor VEGF levels [23]. This model contains 
three compartments, normal tissue, blood, and diseased tissue, to model whole-body VEGF kinetic 
interactions and transport between compartments, developed from experimental observations. The 
model predicts VEGF distribution throughout the body in response to the anti-VEGF recombinant 
humanized monoclonal antibody bevacizumab. This model previously showed that the anti-VEGF 
treatment outcome is dependent on the tumor microenvironment, such as receptor expression, and 
may be affected by heterogeneities across patients. Receptor insertion and trafficking is simplified by 
assuming a constant receptor levels on the cell surface. All receptors are assumed as pre-dimerized 
homodimers, and this model does not account for dimerization kinetics or heterodimers. Model 
components, assumptions, and experimental bases are described in detail in previous publications 
[21-23]. A healthy model excluding the tumor compartment was also developed, which includes all 
of the components in the schematic above the “Healthy Body cutoff” line (Fig. 1.1). Luminal and 
abluminal surfaces of endothelial cells are assumed to have the same receptor levels. Cellular 
heterogeneity is explored within normal physiology and through anti-VEGF drug treatment response 
using these models. An anti-VEGF agent is administered in the model as an injection into the blood 
at time t = 0, and all simulations continue to 3 weeks after anti-VEGF injection [23]. VEGF levels in 
response to altering model parameters are measured as they directly correlate with angiogenesis 
occurrence.    
Applying receptor values to the computational model. Four methods are implemented to 
condense the data distribution into a single VEGFR surface level: median, mode, geometric mean, 
and arithmetic mean. These four methods were chosen as they all have different biases towards 
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choosing a representative value from the population. The mode and median are biased towards values 
that are repeated frequently, the arithmetic mean is biased towards the tail of a population, whereas 
the geometric mean creates a balance between the frequency and the range of values. VEGFR levels 
are updated from the extracted value, and free VEGF in each compartment is simulated up to 3 
weeks after injecting an anti-VEGF drug. Updates are done for VEGFR1 alone, VEGFR2 alone, or 
both using the same extraction method. Free VEGF using parameter updates is compared to control 
which reflects VEGFR levels previously published (1,100 VEGFR1/cell and 700 VEGFR2/cell) [23]. 
 
1.3 Results 
Developing the low bin search method. Optimal bin size for plotting a data set as a histogram 
is determined by fitting to three statistical distributions: Weibull, Gamma, and lognormal, using a 
range of bin sizes. These were chosen due to their characteristic properties: Weibull is a special case 
of the generalized extreme value distribution which approximates the maxima of a finite sequence of 
random variables; Gamma is the maximum entropy probability distribution which chooses the 
unknown distribution that exhibits the highest entropy; and lognormal fits a distribution whose 
logarithm follows a Gaussian. The three statistical distributions are all two parameter distributions, 
and for a given value x  their probability density functions ( )f x are as follows: 
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 
1
( / ) 0
; ,
0 0
k
k
xk x e x
f x k
x

  


  
     

 
                  (1.1) 
 
Gamma: 
6 
 
 
1
0; , ( )
0 0
x
k
k
x e
xf x k k
x

 



  


Γ

                  (1.2) 
 
Lognormal: 
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where k  is the shape parameter,   is the scale parameter, ( )k is the gamma function evaluated at 
k ,  is the mean, and is the standard deviation. The two parameters of each distribution that best 
describe the experimental data are determined using MATLAB. Next it is determined which of the 
three statistical distributions best represents the data by minimizing the sum of squared errors (SSE). 
The SSE for all three distributions is calculated by  
2
1
(y )i
n
i
i
SSE y

        (1.4) 
where n  is the total number of bins in the histogram, iy  is the number of elements in the 
thi  bin, 
and iy  is the statistical distribution evaluated at ix , the center of the 
thi  bin. For example, for a bin 
that ranges between 10 and 20 surface receptors, iy is the value given by the statistical distribution 
evaluated at 15 surface receptors. The histogram is the experimentally obtained receptor data, and 
thus y  is the true value while iy  is the approximated value from fitting the statistical distribution. 
The SSE was used to make two decisions: (1) Decide which statistical distribution fit the data best. 
The best fitting distribution had the lowest SSE amongst the three distributions given the same 
number of bins. However, the best fitting distribution is not dependent on the number of bins. Next, 
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(2) decide the optimal number of bins to define the histogram. The optimal bin number was 
determined by minimizing the SSE the best fit distribution gave across a range of histograms with 
different numbers of bins. Thus, if the Gamma distribution gave the best fit, the optimal bin number
B would be determined as 
 min( ) 5,6,...,mGammaiB SSE i           (1.5) 
where 
Gamma
iSSE is the SSE given by the Gamma distribution fit using a number of bins i , where i
ranges from 1 to m . Note that m  is defined as the maximum number of bins desired to test, and we 
used 500m   bins. Also note that i  starts at 5 bins as starting with a smaller number of bins is not 
practical for representing the data. 
 The histogram is using the optimal bin number is then made. Each bin of index j  in the 
histogram is centered at ja , has a width w , and contains a number of cells jb . Physically, ja  is the 
median surface receptor level in bin j  and jb  is the number of cells in the population whose surface 
receptor level falls in the range of the bin ,
2 2
j j
w w
a a
 
  

. Note that all bins have the same width 
w and that ja  and w  are defined automatically once the optimal bin number is specified. The 
number of cells jb  in a bin is determined by 
1 2 2
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where C is the total number of cells in the data set and r is surface receptor level the index i  cell 
contains.  We define that if r is within the bin range 1
r
i
cell  , otherwise 0
r
i
cell  . For example, a 
bin with 7ja  , 4w  , and 3jb   means 3 cells in the population had between 5 and 9 surface 
receptors.  
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After defining the optimal bin number, we define outliers to account for unwanted data obtained 
from flow cytometry, such as surface receptor levels outside the physiological range. As the data is 
heterogeneous, we define a cutoff method for specifying outliers that utilizes the data shape and the 
optimal bin number. The cutoff is determined by the bin with lowest ja  that also meets the following 
two criteria:  
(1) The number of cells in the bin is less than 1% the number of cells in the largest bin. For 
example, if the largest bin has 500 cells, the cutoff bin must have less than 5 cells.  
(2) The neighboring bins have a number of cells less than 1% the number of cells in the largest 
bin. 
The first criterion ensures the cutoff bin has low occurrence probability, while the second criterion 
ensures uniqueness. Mathematically, the cutoff bin is chosen when the following conditions are met: 
  1 1|Cutoff min 0.01 , 0.01_ , 0.0_ 1j j m j m j ma b b b b b b                  (1.7) 
where jb  is the number of cells contained in the bin of index j , 1jb   and 1jb   are the number of 
cells contained in the neighboring bins, and mb  is the number of cells in the largest bin. Once the 
cutoff bin is determined, data within that bin and all bins to the right are removed. The cutoff point is 
defined using the histogram with the optimal bin number. The optimal binning minimizes the SSE 
that the best fit distribution gives across a range of histograms with different numbers of bins. Thus, 
optimal binning ensures outliers are best defined using the best data representation. Henceforth, we 
refer to this method as the “low bin search” method. Note that the geometric mean, arithmetic mean, 
mode, and median are taken from the complete data set, minus outliers, not from the binned data. For 
this study, we were only interested in defining right hand side outliers, and only bins to the right of 
the largest bin are cutoff candidates. This is due to there being no negative data, in addition to cells 
that either have no or low expression levels. Previous studies have shown that low VEGFR 
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expression does occur in tip-stalk cell selection, where activation of Notch1 receptors downregulates 
VEGFRs [24, 25]. Thus, we did not consider left hand outliers, as our data is consistent with these 
experimental findings. In summary, low bin search (1) determines the best fitting distribution; (2) 
finds the optimal bin number using the best fit distribution; (3) defines a cutoff point using the 
optimal bin number.  
Robustness of low bin search. Two bootstrapping methods were performed using the 
VEGFR1 data obtained from C57BL/6 mice to observe the robustness of low bin search. First, low 
bin search was performed on a random data sample to determine the cutoff value (Fig. 1.2A) and the 
geometric mean (Fig. 1.2B) after defining outliers. Second, randomly selected samples within the 
complete data set were increased by 20% and low bin search determined the cutoff value (Fig. 1.2C) 
and geometric mean (Fig. 1.2D). Sample sizes used were 1,000, 5,000, and 10,000, and 100 trials 
were run for each sample size and bootstrapping pair. The cutoff values found from the random 
sampling fall within a range of 10,000 receptors/cell, whereas the geometric means fall within a 
range of 130 receptors/cell. The cutoff values found after increasing values by 20% fall within a 
range of 2,500 receptors/cell, whereas the geometric means fall within a range of 20 receptors/cell. 
The smallest and largest geometric means for each sampling size and bootstrapping pair were used as 
parameters in the model to determine if bootstrapping caused differences in predicted free VEGF 
levels (Table 1.1). The largest difference in free VEGF in the diseased tissue compartment, compared 
to the complete data set, from all these tests deviated by 5.24%. This deviation is negligible, and low 
bin search is therefore considered robust for our purposes. 
Defining outliers in the HUVEC data. We developed and tested a methodology for defining 
outlying data by examining cell-by-cell VEGFR3 data treated with 1 nM VEGF-A165 (Fig. 1.3). 
These data naturally exhibit a heavy tail, which prevents fitting to Weibull and Gamma distributions 
(Fig. 1.3A). After removing outliers using low bin search, described in the Materials and Methods 
and a cutoff of 2%, which gave the cutoff at 22,000 receptors/cell, the tail was reduced and the 
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Weibull and Gamma distributions better fit the data (Fig. 1.3B). A common data cut-off approach of 
defining outliers as three standard deviations above the mean [26] also resulted in a worse fit than 
that given by low bin search to Weibull and Gamma distributions (Fig. 1.3C). We found that the 
minimum SSE for the Gamma distribution with no outliers removed was approximately 95 times 
larger than the minimum SSE after implementing low bin search. Removing three standard 
deviations above the mean gave an approximately 5 times larger minimum SSE than that using low 
bin search. Likewise for the Weibull distribution, removing no outliers gave an approximately 64 
times larger, and removing 3 standard deviations above the mean gave an approximately 4 times 
larger minimum SSE than that using low bin search. Comparing the number of data points defined as 
outliers between low bin search and three standard deviations shows that low bin search removed 
7.59% more raw data, at most, over all the data sets (Table A.1).   
HUVEC surface receptor data. The VEGFR1, -2, -3, and NRP1 surface expression on 
HUVECs represent distributions that are not normally distributed (Fig. 1.4). As such, this data is not 
represented best by the arithmetic mean in computational modeling. Therefore, we examined fittings 
to Gamma, Weibull, and lognormal distributions (Fig. 1.4). Important features revealed by these 
fittings include the following: VEGFR1, -2, and -3 distributions are positively skewed and best fit to 
the lognormal distribution (Fig. 1.4A-C); whereas NRP1 is best fit to the Gamma distribution (Fig. 
1.4D). For comparison, we fit the receptor data to the Gaussian distribution (Fig. 1.4). For VEGFR1, 
the minimum SSE given by the Gaussian fit was approximately 1,700 times larger than the minimum 
SSE given by the lognormal fit. Likewise for VEGFR2, the Gaussian SSE was approximately 440 
times larger than the lognormal SSE, approximately 130 times larger for VEGFR3, and 
approximately 45 times larger than the Gamma distribution fit to NRP1. NRP1 levels are an order of 
magnitude higher than any VEGFR level (Table 1.2). VEGFR1/2 surface expression on C57BL/6 
and BALB/c mice were also fit to Gamma, Weibull, and lognormal distributions (Fig. A.1, Table 
1.2). For several distributions, such as VEGFR2 on HUVECs, the mode is larger than the other three 
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representative parameters. This is because these parameters were taken from the complete data set 
and not the binned data; thus, the mode may not necessarily be contained in the largest bin. Other 
than these cases, the arithmetic mean is the largest parameter as it has the most bias towards the 
heavy tail of distributions. Since the geometric mean accounts for the tail without biasing it, we 
choose it as the best representing parameter. For comparing these parameters, we will compare the 
geometric mean to the mode as those have the largest discrepancy in value. 
 VEGFR1 affects both initial and quasi-steady state free VEGF concentrations. VEGFR1 and 
VEGFR2 levels on healthy endothelial cells were updated within the tumor model to the levels found 
on endothelial cells of C57BL/6 mice. Changes were made sequentially and in combination to 
observe the sensitivity of the drug treatment to each specific receptor (Fig. 1.5). VEGFR1 is a greater 
effector of free VEGF levels in each compartment: we observe a 40% decrease in initial free VEGF 
levels, before anti-VEGF treatment, in the normal tissue compartment. This occurs when VEGFR1 
levels on healthy endothelial cells are updated from 1,100 VEGFR1/cell (550 abluminal 
VEGFR1/cell and 550 luminal VEGFR1/cell), which was used in the previous model [23] and 
represented ensemble averaged VEGFR1 levels on both C57BL/6 and BALB/c endothelial cells [11], 
to 2,110 VEGFR1/cell (1,055 abluminal VEGFR1/cell and 1,055 luminal VEGFR1/cell), which 
represents the C57BL/6 geometric mean (Table 1.2). VEGFR1-mediated decrease in initial free 
VEGF concentrations in the normal tissue compartment gave a 40% decrease relative to control, 
compared to only a 5% decrease when updating VEGFR2 alone. When both VEGFR1 and VEGFR2 
are updated on the healthy endothelial cells, we observe a 42% decrease in the initial free VEGF 
levels, further confirming that VEGFR1 has a greater effect on free VEGF levels (Fig. 1.5A). We 
also observe a 1.7-fold decrease in initial free VEGF levels relative to control. These updates to the 
normal tissue compartment also affected the blood compartment, where free VEGF levels were 
decreased by 64% when updating VEGFR1 alone, decreased by 17% when updating VEGFR2 alone, 
and decreased by 68% when both receptors are updated (Fig. 1.5B). Updates to either or both 
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VEGFR1 and VEGFR2 had no noticeable effect on initial free VEGF in the diseased tissue 
compartment (Fig. 1.5C). Free VEGF reached quasi-steady state 3 weeks after anti-VEGF 
administration. In the normal tissue compartment, this quasi-steady state level is decreased from 
control levels by 22% when updating VEGFR1 alone. The quasi-steady state free VEGF levels only 
exhibited a modest decrease of 4% when updating VEGFR2 alone, and a total decrease of 25% when 
both receptors are updated (Fig. 1.5A). In the blood compartment, this quasi-steady state level is 
decreased from control levels by 28% when updating VEGFR1 alone, decreased only 9% when 
updating VEGFR2 alone, and had a total decrease of 35% when both receptors are updated (Fig. 
1.5B). In the diseased tissue compartment, this quasi-steady state level is decreased from control 
levels by 25% when updating VEGFR1 alone, decreased only 5% when updating VEGFR2 alone, 
and had a total decrease of 28% when both receptors are updated (Fig. 1.5C).    
Representation of VEGFR levels effects model predictions. Since slight changes in VEGFR 
levels cause varying effects on the initial and quasi-steady state free VEGF concentrations, we next 
survey the data representation approaches with regards to their predicted anti-VEGF drug treatment 
efficacy. This was achieved by examining how updating both VEGFR1 and VEGFR2 controls the 
fold change in free VEGF levels after anti-VEGF injection, which we define as: 
quasi-steady state
0
[ ]
[ ]
t
t
VEGF
VEGF


. An increase in free VEGF levels after anti-VEGF injection is defined as a 
positive change, while a decrease is defined as a negative change. We observe a larger magnitude 
change in free VEGF in the blood and normal tissue compartments relative to control when the 
model is updated to reflect the VEGFR1 and VEGFR2 mode, median, geometric mean, and 
arithmetic mean on healthy endothelial cells from C57BL/6 (Fig. 1.6A) and BALB/c (Fig. 1.6B) 
mice. All receptor levels give a negative free VEGF fold change in the diseased tissue compartment, 
which indicate decreased VEGF levels.  
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We observe that the choice of data representation alters the predicted change in free VEGF 
concentrations, with the largest difference in predicted treatment efficacy given between the mode 
and arithmetic mean. We predict a 3.1 fold change in VEGF concentration in the blood compartment 
when the arithmetic mean from the C57BL/6 data is inserted into the model (2,970 VEGFR1/cell and 
2,180 VEGFR2/cell) (Table 1.2); whereas, we predict a 1.8 fold change in the blood compartment 
with the mode (1,820 VEGFR1/cell and 2,860 VEGFR2/cell), and 2.1 fold change with the 
geometric mean (2,100 VEGFR1/cell and 1,540 VEGFR2/cell), from the same data set (C57BL/6) 
(Fig. 1.6A). The BALB/c data give similar results, predicting a 3.9 fold change in VEGF 
concentration in the blood compartment when updating the arithmetic mean into the model (3,850 
VEGFR1/cell and 2,690 VEGFR2/cell) (Table 1.2); whereas, we predict a 1.6 fold change in the 
blood compartment with the mode (1,700 VEGFR1/cell and 1,200 VEGFR2/cell) and a 2.7 fold 
change with the geometric mean (2,700 VEGFR1/cell and 1,900 VEGFR2/cell) (Fig. 1.6B). We 
choose the geometric mean as the best representation of the receptor levels, and thus the most 
accurate fold changes, as it accounts for the tail of the distribution unlike the mode, but doesn’t bias 
the tail like the arithmetic mean. 
Free VEGF levels are sensitive to VEGFR1 levels. Since receptor levels can alter predicted 
anti-VEGF drug efficacy (Fig. 1.5, 1.6), we develop a healthy body model (absence of disease 
compartment) to better examine the receptor roles. We also add in vitro (Fig. 1.7A) or ex vivo (Fig. 
1.7B-C) data in the healthy body model using all representative parameters (Table 1.2). The normal 
tissue and blood compartments give lower magnitude free VEGF levels compared to control for all 
simulations performed (Fig. 1.7). Initial free VEGF levels, relative to normalized control levels, 
using in vitro HUVEC data is notably different from the ex vivo C57BL/6 mouse data in the normal 
tissue compartment using the median (0.41 in vitro, 0.60 ex vivo) and mode (0.29 in vitro, 0.61 ex 
vivo). The difference between these two in the blood compartment is noticeably different using the 
geometric mean (0.21 in vitro, 0.30 ex vivo), median (0.14 in vitro, 0.33 ex vivo), and mode (0.06 in 
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vitro, 0.32 ex vivo) (Fig. 1.7A-B). BALB/c free VEGF levels in the normal tissue compartment are 
notably different from those of HUVEC with the median (0.41 in vitro, 0.49 ex vivo) and mode (0.29 
in vitro, 0.70 ex vivo), as well as in the blood compartment with the median (0.14 in vitro, 0.21 ex 
vivo) and mode (0.29 in vitro, 0.48 ex vivo) (Fig. 1.7A, 1.7C). Free VEGF concentrations versus time 
are also given (Fig. A.2). Having added ex vivo VEGFRs to the normal tissue and in vitro and ex vivo 
VEGFRs in a tumor-free model, we compare adding in vitro and ex vivo VEGFRs to the tumor 
model. Free VEGF levels obtained using ex vivo versus in vitro VEGFR1 in the tumor model differ 
by 54% at most with the mode and by 25% at most with the geometric mean (Fig. A.3).   
Tumor growth increases free VEGF levels. To observe how VEGF levels may change with 
tumor progression, we simulate 0.62 cm3 and 1.45 cm3 tumor volumes, corresponding to tumors that 
have been growing for 3 weeks and 6 weeks, respectively. The tumor size and VEGFR1/2 surface 
levels on tumor cells and tumor endothelial cells (tEC) were obtained from mouse xenografts [13]. It 
is observed that receptor distributions on the tumor cells and tEC exhibited multiple distributions. 
Specifically, these tumor data contain at least 2 subpopulations arising based on size with the smaller 
cells containing multiple subpopulations based on receptors/cell. Due to these subpopulations, these 
data cannot be fit by the continuous probability distributions that we have used to fit our in vitro 
endothelial cell (HUVEC) and ex vivo skeletal muscle endothelial cell data. When subpopulations are 
qualitatively observed, fitting to mixtures is a common approach [27, 28]. We have previously 
modeled these populations as mixtures and shown that they fit well to the multi-component 
lognormal mixture model [13]. However, prior computational models have represented cellular data 
using the arithmetic average. Thus to arrive at a more accurate quantitative tumor cell and tEC data 
representation, we examine tri-modal Gaussian mixture models here. While non-Gaussian mixture 
models, such as the Weibull mixture model [29], have more flexibility in shape than the Gaussian 
mixture model, due to both the goodness of fit and simplicity in computational resources, we believe 
the Gaussian mixture model is the best model choice, and deem it unnecessary to perform additional 
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fitting to other mixture models. Simulations are performed (1) using the tri-modal mixture 
distribution and (2) individually inserting each component (mean) comprising the tri-modal mixture. 
Receptor levels within the mixture model are determined by weighting the individual Gaussian 
distribution parameters with their respective densities and summing. The distribution and mixture fits 
to receptor levels on tumor cells and tECs grown for 3 weeks and 6 weeks are shown (Fig. 1.8-1.9). 
The densities are ordered with “Density 1” having the highest cell frequency and “Density 3” having 
the lowest frequency. As the tumor grows from 3 weeks to 6 weeks, VEGFR1 subpopulations on the 
tumor cells are more highly expressed (Fig. 1.8A, 1.9A), but VEGFR2 levels only slightly change 
(Fig. 1.8B, 1.9B). For example, “Density 1” gives the geometric mean at 2,900 VEGFR2/tumor cell 
(Table 1.3) at week 3 (Fig. 1.8B), and “Density 1” gives the geometric mean at 3,150 
VEGFR1/tumor cell (Table 1.3) at week 6 (Fig. 1.9B). VEGFR1/2 levels on tECs decrease 
throughout tumor growth. For example, “Density 1” gives the geometric mean at 13,000 
VEGFR1/tEC (Table 1.3) at week 3 (Fig. 1.8C), and “Density 1” gives the geometric mean at 600 
VEGFR1/tEC (Table 1.3) at week 6 (Fig. 1.9C). Likewise, “Density 1” gives the geometric mean at 
1,450 VEGFR2/tEC (Table 1.3) at week 3 (Fig. 1.8D), and “Density 1” gives the geometric mean at 
600 VEGFR2/tEC (Table 1.3) at week 6 (Fig. 1.9D). Gaussian distributions corresponding to 
receptor subpopulations express large differences in receptor levels (Table 1.3). 
 At tumors grown to 3 weeks, there are no noticeable changes in free VEGF levels in either 
the normal or the blood compartments when only the tEC receptor levels are updated, for all receptor 
distributions (Fig. 1.10A-B, 1.10D-E, 1.10G-H). However, initial free VEGF levels before anti-
VEGF administration in the diseased tissue compartment is highly dependent on the VEGFR1 levels 
on tECs (Fig. 1.10C, 1.10F, 1.10I). Free VEGF levels in the diseased tissue converge to 
approximately 41 pM after anti-VEGF treatment. 
 Interestingly, using the VEGFR1 geometric mean on the “Density 2” distribution (Fig. 1.8C), 
which is 69,500 VEGFR1/cell (Table 1.3), gives an increase in free VEGF levels in the diseased 
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tissue after anti-VEGF treatment, corresponding to a 1.64 fold change in free VEGF (Fig. 1.10C). 
Sensitivity analysis, performed by observing free VEGF levels in response to parameter 
perturbations, reveals that decreasing the VEGFR1 membrane insertion rate on the tECs transforms 
anti-VEGF treatment from a pro-angiogenic response to anti-angiogenic (Fig. 1.11). The insertion 
rate defines the rate at which receptors are inserted into the cell membrane, such as through receptor 
trafficking, making those receptors available for ligand binding. Sensitivity analysis also reveals that 
anti-VEGF treatment was ineffective for subpopulations containing more than 35,000 VEGFR1/cell 
(data not shown). 
As with tumors grown to 3 weeks, tumor grown to 6 weeks show no noticeable change in 
free VEGF levels in the normal and blood compartments when only the tEC receptor levels were 
updated (data not shown). Initial free VEGF levels in the diseased tissue compartment, before adding 
anti-VEGF, are dependent on tEC receptor levels, but converge to approximately 41 pM after 
administering anti-VEGF (Fig. 1.12A-C). Free VEGF levels in the diseased tissue compartment 
before anti-VEGF treatment is higher in the 6 week tumor than in the 3 week tumor. For example, 
using the geometric mean and updating both tEC receptors, the mixture model of the 6 week tumor 
gave a free VEGF concentration of 93.77 pM (Fig. 1.12C) while the 3 week tumor gave 49.24 pM 
(Fig. 1.10I). The tumor cell receptors are updated in a similar fashion for 3 week (Fig. A.4) and 6 
week tumors (Fig. A.5). Updating VEGFR1/2 levels on the tumor cells either individually or 
simultaneously gave no noticeable change to the free VEGF levels in the normal tissue and blood 
compartments for all receptor distributions, but free VEGF levels are highly sensitive to the tumor 
cell receptor levels in the diseased tissue (Fig. A.4, A.5).  
Remark: The receptor levels and tumor sizes are obtained using mouse xenograft models: 
human tumor inoculated in mouse; therefore, the tumor cells are human and the tumor endothelial 
cells are murine. However, all values (mouse and human) are used in simulating an adult human. 
This simplification is acceptable as we are only interested in observing trends in the free VEGF 
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levels in response to receptor heterogeneity. These observed trends are still physiologically relevant 
for humans as we assume the tumor size ratio to receptor levels are the same for adult humans.   
 
1.4 Discussion 
 In this study, we introduce a novel method for quantitatively representing heterogeneous 
populations, and show how accounting for heterogeneity affects drug efficacy predictions. We show 
how low bin search simultaneously define outliers and optimizes heterogeneous data binning. This is 
accomplished by performing goodness of fit tests to various statistical distributions, where the best 
fitting statistical distribution is determined. The best fitting statistical distribution is then used to 
define outliers and then representative parameters from the data are extracted. We used these 
parameters in a tumor angiogenesis model, where we predict that free VEGF levels are sensitive to 
VEGFR1. Using the simplified healthy body model, we also observed that free VEGF levels are 
sensitive to VEGFR1 expression, indicating that cellular heterogeneity is essential in both healthy 
and cancerous angiogenesis models. We also predict that anti-VEGF drug efficacy is sensitive to 
subpopulations present in tumor cells and tECs. 
Defining outliers in heterogeneous populations. We introduced low bin search, a novel 
method to define outliers in a heterogeneous distribution that follows the algorithm: (1) determining 
the best fitting distribution with the minimum SSE; (2) finding the optimal bin number by 
minimizing the SSE the best fit distribution gives over a range of histograms; (3) defining the cutoff 
point from the optimal bin number. The cutoff point eliminates the first bin that meets two criteria: 
(1) the number of cells in the cutoff bin is less than 1% the number of cells in the largest bin; (2) the 
neighboring bins also have a number of cells less than 1% the number of cells in the largest bin. The 
theoretical basis is as follows: the first criterion ensures the cutoff bin has low occurrence 
probability, while the second criterion ensures uniqueness. Thus, as low bin search is an algorithmic 
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approach for defining outliers with a theoretical basis for defining the cutoff point, we define it as a 
method as opposed to a heuristic rule, which pertains to trial-and-error methods of problem solving 
when an algorithmic approach is infeasible or a theoretical basis is lacking. This novel method 
represents an important development, since outlier detection is essential for removing unwanted data 
or finding features that occur at low probability. Outlier detection has been tackled for mass 
spectrometry by calculating the Mahalanobis distance a distribution gives to all other experimental 
runs and eliminating those with suspiciously high distances [30]. Another algorithm uses projection 
and quantile regression to discard values that do not follow the general trend given by the data set 
[31], but is computationally intensive for many data points. These methods are useful for removing 
experimental runs that exhibit high variation, but not for defining outliers within a data set. Outliers 
in gene expression can be defined by incorporating probability distribution functions and comparing 
to multiple experimental runs [32]. However, this method for gene expression requires a priori 
knowledge for population distribution functions, which may not be available. The low bin search 
method we present requires no a priori knowledge in regards to what statistical distribution 
represents the data, and will define outliers within any type of distribution.  
Automatic gating and outlier removal in flow cytometry. Flow cytometry is a high-throughput 
tool for cell-by-cell analysis, and requires gating to separate cell populations. Bashashati and 
Brinkman have emphasized the need to completely automate flow cytometry data analysis, and 
provided a theoretical framework for this analysis [33]. However, few methods for automatically 
gating flow cytometry data and defining outliers within gated data exist. One such method for 
automated gating is cluster analysis, which groups cells with similar fluorescence patterns, such as by 
K-means clustering [34, 45]. Density based merging places the flow cytometry data on a 2-
dimensional grid, and groups data based on grid point densities [36]. K-means cluster is limited in 
that clusters must be convex, and thus neglect subpopulation features exhibited by any other shape. 
Density based merging is limited to gating 2-dimensional data, such as data containing forward 
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scatter and side scatter information only, and thus cannot gate data with more than two features. 
There is a need to expand on current methods to gate high dimensional data and better capture 
subpopulations. Thus, due to current automated gating limitations, gating typically involves manually 
selecting cell populations for these data as we have done in the past [10-13]. The low bin search 
method we developed could be implemented in addition to automatic gating to search through and 
remove outliers within a gate. This would provide less manual pre-processing of flow cytometry 
data, which is time consuming and subject to human error and reproducibility issues.   
Binning optimization. Low bin search presented here bins data based on the data shape and 
does not require transforming statistical distributions. Binning is important as it reduces data 
dimensionality and organizes data based on similar features. Mathematic operations performed on 
binned data, such as fitting statistical distributions, are affected by the binning method. Thus, it is 
important to optimize the number of bins such that statistical distributions can best represent the data. 
Current approaches are limiting because they arbitrarily assign a number of bins to represent the data 
based solely on the number of data points. For instance, two commonly used software packages, 
MATLAB and Palisade, determine the number of bins based on n and rounding up to the nearest 
integer, or by 10log( )n and rounding down to the nearest integer, for n  data points, respectively. To 
improve these current approaches, it is necessary to develop methods that bin based on specific data 
features, in order to best represent each data set individually. Thus, we created low bin search to bin 
and represent data sets that optimizes the fit to the best fitting statistical distribution. For comparison, 
low bin search determined that NRP1 levels on HUVECs are optimally distributed over 101 bins, 
whereas MATLAB would use 172 bins and Palisade would use 44 bins. Using these bin numbers, the 
total error was calculated as the sum of the individual SSE from the Weibull, Gamma, and lognormal 
fits. For this example, MATLAB gave a total error 24.71% larger than that given by low bin search, 
while Palisade gave a total error 77.41% larger than low bin search. Probability Binning is another 
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binning method, which splits up the data such that every bin may not have the same width, but 
contains an equal number of events [37]. However, this method shapes the histogram into a uniform 
distribution, and requires transforming statistical probability distributions for goodness of fit tests. 
Low bin search not only effectively defines outliers, but also optimizes data binning. 
Determining the best fitting statistical distributions. We show that it is necessary to 
determine the goodness of fit a statistical distribution gives to a heterogeneous data set to find the 
best fitting distribution. There are many metrics for testing the goodness of fit between observed data 
and statistical distributions. We chose SSE as the test metric as it weights every bin equally. By 
changing the number of bins, the cluster mean changes without altering the best fitting distribution, 
allowing the SSE using different bin numbers to be compared. We optimize the bin number with the 
minimum SSE, and the outliers are then defined. Thus, using SSE to measure goodness of fits not 
only determines the best fit distribution, but simultaneously defines outliers. For binned data, SSE 
compares the observed hits in a bin to that expected from a statistical distribution, using the bin 
center. Another test metric, Chi-squared, differs as it weights each bin by the number of hits it 
contains [38]. Overfitting is a significant problem that negates predictive power, and results in bad 
data fitting. Overfitting occurs when a statistical model is overly complex to explain the data, 
typically describing random noise or errors instead. Overfitting generally occurs when there are a 
relatively high number of fit parameters to the number of observations. To prevent overfitting, low 
bin search performs the following: (1) finds the best fitting distribution; for example, in the case of 
VEGFR3 this best fitting distribution is the lognormal distribution (Fig. 1.4C); (2) optimizes the 
number of bins by minimizing the SSE given by the best fitting distribution (Eqn 1.5); (3) determines 
the cutoff point (Eqn 1.7). The optimal bin number is found by minimizing the SSE the best fitting 
distribution gives, as opposed to minimizing the SEE globally for all distributions, reducing the 
overfitting risk. Additionally, all data sets contain greater than 20,000 observations, but rather than 
attempting to fit all observations, we fit to data represented by the optimal bin number. This further 
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reduces fitting parameters and the overfitting risk. Further developing low bin search could include 
comparing goodness of fit tests to determine the most robust test metric.   
Statistical distributions best fitting data sets. We have found that VEGFRs best fit to 
lognormal distributions under all experimental conditions, whereas NRP1 best fit to the Gamma 
distribution when untreated and to the Weibull distribution when treated with VEGF-A or VEGF-C. 
We hypothesize VEGFRs best fit lognormal distributions because they have heavy tails not present 
in NRP1 distributions. The heavy tail shows that some cells in the population express receptors at a 
higher level, which may be used by the cell population to elicit a specific response. Lacking a heavy 
tail in the NRP1 distributions indicates that the cell population keeps NRP1 levels relatively 
consistent across the population. Previous studies have shown that NRP1 expression is important for 
T-cell stability and survival, and may have a similar role in endothelial cells [39]. Additionally, 
NRP1 is a co-receptor for VEGF-A165, and appears to play a vital role in vascular morphogenesis 
[40]. However, it is not known why NRP1 is expressed at higher levels than VEGFRs. Additionally, 
better understanding the connection between the best fitting statistical distribution and the population 
role is needed.  
Quantifying a heterogeneous population. Due to the VEGFRs being best fit to lognormal 
distributions, we chose the geometric mean as the best heterogeneous data representation. This is 
because the geometric mean accounts for the heavy tail, unlike the mode or median, but it is not 
biased towards the tail like the arithmetic mean. We do not want to bias the heavy tail as it only 
represents a small subset of the cells in the population. For example, VEGFR1 on tECs at 3 weeks 
had a heavy tail that accounted for approximately 3% the total cells in the population. The three 
statistical distributions were chosen due to their characteristic properties; Weibull is a special case of 
the generalized extreme value distribution which approximates the maxima of a finite sequence of 
random variables; Gamma is the maximum entropy probability distribution which chooses the 
unknown distribution that exhibits the highest entropy; and lognormal fits a distribution whose 
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logarithm follows a Gaussian. Representative parameters were chosen as they are the best parameters 
that represent the three statistical distributions; they are calculated the same for each distribution 
without biasing one distribution over the other. These representation parameters are thus generalized 
for any heterogeneous data set and require no a priori knowledge. Expanding low bin search to 
include more statistical distributions will allow for more accurate heterogeneous data representations. 
VEGFR1 levels control free VEGF levels. Free VEGF levels are more sensitive to VEGFR1 
than VEGFR2: using the C57BL/6 geometric mean from healthy endothelial cells, we observed that 
updated VEGFR1 alone resulted in a steady state free VEGF concentration change of 24.6% 
compared to control in the diseased tissue, while VEGFR2 alone gave a 4.8% change. As VEGFR1 
and VEGFR2 on the healthy endothelial cells are altered, we would expect free VEGF levels in the 
healthy tissue and blood compartments to change as those compartments are where the healthy 
endothelial cell receptors are located. Previous studies confirm that free VEGF concentrations are 
more sensitive to VEGFR1 than VEGFR2 levels, due to a higher binding affinity to VEGFR1 [10]. 
As such, VEGFR1 is typically identified as a decoy receptor [41]. However, more insight is 
necessary into the complete function of VEGFR1. 
VEGFR1 is important for cell migration. We have shown a high VEGF binding affinity and 
sensitivity to VEGFR1, indicating that VEGFR1 plays a more important role than simply being a 
decoy. For HUVECS, VEGFR1 mediates p38 phosphorylation, which controls cell migration 
through actin reorganization, whereas VEGFR2 mediates ERK1/2 phosphorylation, which mediates 
cell proliferation [42, 43]. VEGFR1 is expressed at high levels on BALB/c fibroblasts (36,000 
rec/cell) [11], and fibroblast migration can be abolished with bevacizumab [44]. This VEGFR1 
migratory function is also observed in macrophages [45, 46], monocytes [47-49], and endothelial 
cells [50]. If the VEGFR1 migratory function observed in these studies also translates to the tumor 
endothelial cells, this would explain the high VEGF binding to VEGFR1 observed in our 
computational model.  
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Several studies have also suggested a role for upregulated VEGFR1 in migration. In murine 
hindlimb ischemia, VEGFR1, as well as proliferation markers and migration, are upregulated on 
ischemic endothelial cells ten days post ischemic induction; this time point coincides with 
accelerated perfusion recovery to the hindlimb [12]. Another study has shown that VEGFR1 is 
expressed 3 days after embyroid body induction, a time marked by significant migratory phenotype 
by endothelial PmTc1 cell lines. VEGFR1 expression is sustained through day ten, at which point the 
endothelial-like cells arrange in a distinct pattern to line vessel-like structures [51]. Gastric ulcers 
were induced in RAG2 mice, and gastric ulcer healing in VEGFR1 knockout mice resulted in 
decreased CD31 mRNA levels and decreased microvessel density compared to wildtype mice, 
indicating that VEGFR1 has an important role in cell migration and vessel formation in gastric ulcer 
healing [52]. Additionally, VEGFR1 expression on highly metastatic 3LL-LLC tumor cells induces 
MMP9 expression in premetastatic lung endothelial cells and macrophages. MMP9 then breaks down 
the extracellular matrix and allows tumor cell migration [53]. It should be noted that VEGFR1 does 
not appear to modulate neuronal migration – lowly expressed VEGFR1 on cortical neuron cells was 
blocked with a polyclonal antibody and neurogenesis was not hindered [54]. Likewise, neurons 
expressed no VEGFR1 mRNA when the cells were treated with VEGF-A165, indicating VEGFR1 is 
unimportant for neurogenesis [55]. Altogether, our results, and these previous studies, support the 
idea that VEGFR1 is upregulated at early angiogenesis stages and is a crucial regulator of cell 
migration. 
The healthy body model assures physiological relevancy. For systems biology studies, 
building and testing model modules assures that individual model pieces give physiologically 
relevant results before adding additional modules. The healthy body model was used, as it allows the 
heterogeneity effects to be observed in a simplified model. This allowed us to sequentially insert 
experimentally obtained receptor levels on healthy endothelial cells and observe the effect in the 
healthy tissue compartment they reside in, without any cross talk from the tumor. Initial model 
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versions contained a single, normal tissue compartment, and provided insight into the importance in 
VEGFR levels in determining VEGF concentration [56]. This iterative process allows individual 
molecules or parameters to be understood, as well as provides a troubleshooting basis for more 
complex models.    
Tumor associated cells control drug efficacy. VEGFR1/2 levels on tumor cells and tECs play 
an important role in determining drug efficacy. By observing free VEGF levels in the diseased tissue 
compartment, we have shown that anti-VEGF treatment is ineffective against specific tumor cell and 
tEC subpopulations that have high expression levels. These high expression levels consequently 
increased the membrane protein insertion rate, and we showed that decreasing the insertion rate 
recovered the anti-angiogenic result from anti-VEGF treatment. For these subpopulations, receptor 
mRNA could be targeted to reduce receptor levels or the insertion rate could be decreased by 
inhibiting insertion proteins [57]. tECs can also form various vessel types, creating a highly 
heterogeneous tumor vasculature [58]. It is possible the formed blood vessel type varies with time, 
with early vessels being more responsive to anti-VEGF treatment and late vessels portraying anti-
VEGF resistance [59]. The hierarchy of large arteries bifurcating into successively smaller conduits 
present in normal blood vessel networks is missing in tumor vasculature, which often lack sufficient 
blood flow, pericyte coverage, and exhibit leakiness and dilation [60, 61]. These changes in tumor 
vasculature could account for the heterogeneous subpopulations that we observe in tECs. One study 
aiming to characterize cell subpopulation heterogeneity decomposed populations based on basal 
signaling markers and showed cells with similar basal signaling to have similar drug sensitivities 
[62], while others have characterized subpopulations through signaling markers after applying drug 
treatment [63]. Singh et al noted that characterizing subpopulations in an ensemble manner may be 
required to distinguish biological or functional differences in subpopulations. These tEC 
subpopulations and heterogeneities in vessel formation and properties indicate a need to better 
characterize cell subpopulations and their potential responses to drug treatment. Our work provides 
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insight into subpopulation dispersion with regards to VEGFR membrane localization and how this 
affects drug treatment. 
Incorporating cellular heterogeneity with signaling pathways. We present here how receptor 
heterogeneity affects ligand binding kinetics and ligand distributions. The model implemented here is 
a simplified angiogenesis model as it does not account for receptor trafficking or cell signaling 
pathways. However, computational studies require building models in an iterative manner to ensure 
physiological relevancy, and the lack of previous studies computationally exploring cellular 
heterogeneity necessitates this simplified model. For instance, early computational models sought to 
reveal the mechanism of EGFR activation via EGF binding using simplified models to examine the 
interaction kinetics [64, 65]. Later models then sought to better understand the cellular complexity 
pertaining to EGFR activation by mapping the downstream signaling and receptor internalization [19, 
66, 67]. However, VEGF models have not yet reached the sophistication that EGF models have [68], 
highlighting the necessity to examine VEGF model sensitivity. Prior sensitivity analysis revealed that 
VEGFRs are the primary controller of free VEGF levels [56]. Early VEGF models first examined 
ligand binding kinetics to VEGFR [69] or receptor dimerization kinetics [70] in simplified models. 
Later studies increased complexity by modeling tumor angiogenesis to examine the effect of the 
tumor microenvironment on anti-VEGF treatment efficacy [71, 72], and included targeting specific 
VEGF isoforms [73]. Recent models incorporated receptor trafficking and specific signaling 
pathways to better understand cellular activity upon ligand binding [41, 68] using ensemble averaged 
receptor levels. Therefore, accurate VEGFR representations are necessary for accurate model 
development. Our ability to obtain these experimental data on a cell-by-cell level allowed us to now 
examine the most appropriate way to analyze the data, represent the data, and extract representative 
parameter(s) for use in models. Here, we show that these are critical steps for accurate model 
development. We similarly show how data representation affects the ligand binding kinetics and 
ligand distribution in a simplified model. We use free VEGF levels as the functional model output, 
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since it is the primary signaling molecule in angiogenesis [74], its secretion by tumor mediates tumor 
growth and metastasis [75], and a meta-analysis has shown that VEGF levels in blood and serum is 
significantly elevated in cancer patients [76]. We believe that our work presents a novel foundation 
for understanding heterogeneity, particularly in tumor, and with such a foundation, we can now 
incorporate downstream signaling for more reliable predictive power. 
Concluding remarks. Here we show how the choice of data representation in heterogeneous 
populations can affect anti-angiogenic drug efficacy predictions. While we select a single value from 
the populations to represent the heterogeneity (every cell in the population contains that 
representative parameter), we present significant analysis to support the parameter representation; 
thereby establishing the need to fully analyze experimental data and comprehensively identify the 
effect of data representation on model predictions. With the advent of high-throughput cell-by-cell 
data, compartments should incorporate these cell-by-cell data as individual cells with simulations 
probing the aggregation of these cell-by-cell dynamics. Such approaches, applied to our system, 
would require expanding the single normal tissue compartment to 1h   compartments for h  healthy 
endothelial cells, expanding the diseased tissue compartment to 1t d   compartments for d  tECs 
and t  tumor cells, and expanding the blood compartment to 1h t   compartments. Even for 
relatively low numbers of cells, say 100,000 of each type, we estimate a single simulation could take 
upwards of 170 hours/7 days on the system used for this study. This increased complexity would 
require supercomputing, split among multiple processors to obtain reasonable solution times. 
Extensions such as these would advance new insight into how a system of distinct cells interacts to 
achieve a specific response.  
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1.5 Figures and Tables 
 
 
Figure 1.1: Schematic of the compartments and major components included in the VEGF model.   
The VEGF model contains a normal tissue, blood, and diseased tissue compartment. VEGF interacts anti-
VEGF, GAG chains, and with its receptors VEGFR1/2, on tumor cells and Myocytes, as well as NRP1/2 
on endothelial cells. The luminal surface of the endothelial cells resides in the blood compartment, 
whereas the abluminal side resides in the normal tissue compartment on healthy endothelial cells and the 
diseased tissue compartment on tECs. VEGF is secreted by the tumor in the diseased compartment and 
tissue in the normal tissue compartment. VEGF is also secreted and lymphatically drained to the blood 
compartment where it is cleared. VEGF is also permeable through the blood vessel wall. A thorough 
description of the model containing a complete list of species and parameters can be found in Finley et al 
[23]. The tumor model contains all of the shown components, while the healthy model contains only 
those above the “healthy model cutoff” line.   
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Figure 1.2: Bootstrapping low bin search. 
The cutoff value and geometric mean determined from low bin search (A-B) applied to a random subset 
(A-B) and after adding 20% error to random data (C-D) using the VEGFR1 data set from C57BL/6 mice. 
Sample sizes are 1,000, 5,000, and 10,000. Each sample size and bootstrapping method pair contains data 
from 100 trials, however, due to point clustering, the plots may appear to contain less trials. Red lines 
show the cutoff (15,642 rec/cell) and geometric mean (1,053 rec/cell) given by low bin search using the 
complete data set. 
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Figure 1.3: Effectiveness of low bin search.  
Effect of low bin search on distribution fitting using HUVEC data of VEGFR3 treated with VEGF-A. (A) 
Weibull and Gamma distributions were unable to fit the raw data. (B) After implementation of the cutoff 
method, Weibull and Gamma distributions were able to fit the data. (C) Comparison to removing all data 
3 standard deviations above the mean, which is also unable to properly fit the data. Goodness of fit was 
measured by the combined sum of squared error of each statistical distribution. 
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Figure 1.4: Statistical distribution fits to in vitro receptor populations.  
Cell-by-cell analysis of (A) VEGFR1, (B) VEGFR2, (C) VEGFR3, and (D) NRP1 distributions on in 
vitro human endothelial cells. Each distribution was fit to Weibull (generalized extreme value 
distribution), Gamma (maximum entropy probability distribution), and lognormal (logarithm is normally 
distributed) probability density functions. The parameters for the best fit distributions are given in Table 
1.2. 
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Figure 1.5: Effect of VEGFR1 and VEGFR2 levels on anti-VEGF efficacy. 
Comparison of updating the model by adding experimental VEGFR1 levels only, VEGFR2 levels only, 
and both compared to the control. Updated VEGFR1 and VEGFR2 values represent geometric means of 
C57BL/6 distributions (2,100 VEGFR1/cell and 1,540 VEGFR2/cell). The control reflects previously 
published VEGFR1 and VEGFR2 levels (1,100 VEGFR1/cell and 700 VEGFR2/cell) [23]. Free VEGF 
concentration is shown in (A) the normal tissue compartment, (B) the blood compartment, and (C) the 
diseased tissue compartment. An optimized anti-VEGF agent is added at t = 0 and the VEGF 
concentration response is simulated to 3 weeks after injection. 
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Figure 1.6: Effect of receptor levels on free VEGF fold change after anti-VEGF treatment. 
Fold change in free VEGF levels in response to anti-VEGF treatment using different representative 
receptor levels from the (A) C57BL/6 (C57) and (B) BALB/c (BAL) mice data. VEGFR1 and VEGFR2 
levels were both updated in the model with geometric mean (2,100 VEGFR1/C57, 1,540 VEGFR2/C57, 
2,700 VEGFR1/BAL, 1,900 VEGFR2/BAL), arithmetic mean (2,970 VEGFR1/C57, 2,180 
VEGFR2/C57, 3,850 VEGFR1/BAL, 2,690 VEGFR2/BAL), mode (1,820 VEGFR1/C57, 2,860 
VEGFR2/C57, 1,700 VEGFR1/BAL, 1,200 VEGFR2/BAL), and median (2,050 VEGFR1/C57, 1,510 
VEGFR2/C57, 2,650 VEGFR1/BAL, 1,800 VEGFR2/BAL). Fold change is relative to control fold 
change, reflecting the normalized fold change obtained using previously published receptor levels (1,100 
VEGFR1/cell and 700 VEGFR2/cell) [23]. 
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Figure 1.7: Receptor level effect on steady state free VEGF levels in the healthy body model. 
Free VEGF at steady state in the healthy body model by updating VEGFR1 and VEGFR2 levels from the 
(A) HUVEC, (B) C57BL/6 (C57), and (C) BALB/c (BAL) distributions. VEGFR1 and VEGFR2 levels 
were both updated in the model with geometric mean (2,100 VEGFR1/C57, 1,540 VEGFR2/C57, 2,700 
VEGFR1/BAL, 1,900 VEGFR2/BAL, 2,530 VEGFR1/HUVEC, 5,260 VEGFR2/HUVEC), arithmetic 
mean (2,970 VEGFR1/C57, 2,180 VEGFR2/C57, 3,850 VEGFR1/BAL, 2,690 VEGFR2/BAL, 3,000 
VEGFR1/HUVEC, 6,950 VEGFR2/HUVEC), mode (1,820 VEGFR1/C57, 2,860 VEGFR2/C57, 1,700 
VEGFR1/BAL, 1,200 VEGFR2/BAL, 2,720 VEGFR1/HUVEC, 11,400 VEGFR2/HUVEC), and median 
(2,050 VEGFR1/C57, 1,510 VEGFR2/C57, 2,650 VEGFR1/BAL, 1,800 VEGFR2/BAL, 2,500 
VEGFR1/HUVEC, 5,350 VEGFR2/HUVEC). The control reflects previously published VEGFR1 and 
VEGFR2 levels (1,100 VEGFR1/cell and 700 VEGFR2/cell) [23]. 
 
 
34 
 
 
Figure 1.8: Gaussian mixture model of tECs and tumor cells at 3 weeks of tumor growth. 
Gaussian tri-modal mixture models and the individual Gaussian distributions making up the mixture 
model for (A) VEGFR1 on tumor cells, (B) VEGFR2 on tumor cells, (C) VEGFR1 on tECs, and (D) 
VEGFR2 on tECs at 3 weeks of tumor growth. “Density 1” corresponds to the Gaussian with highest 
weight in the mixture model, “Density 2” is the second highest weight, and “Density 3” is the lowest 
weight. 
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Figure 1.9: Gaussian mixture model of tECs and tumor cells at 6 weeks of tumor growth. 
Gaussian tri-modal mixture models and the individual Gaussian distributions making up the mixture 
model for (A) VEGFR1 on tumor cells, (B) VEGFR2 on tumor cells, (C) VEGFR1 on tECs, and (D) 
VEGFR2 on tECs at 6 weeks of tumor growth. “Density 1” corresponds to the Gaussian with highest 
weight in the mixture model, “Density 2” is the second highest weight, and “Density 3” is the lowest 
weight. 
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Figure 1.10: Effect of tEC receptor levels on anti-VEGF treatment at 3 weeks of tumor growth. 
Free VEGF in the normal tissue, blood, and diseased tissue compartments in response to anti-VEGF 
treatment after updating (A-C) VEGFR1 alone, (D-F) VEGFR2 alone, and (G-I) both receptors on the 
tECs at 3 weeks of tumor growth. “Density 1” (D1) corresponds to the Gaussian with highest weight in 
the mixture model, whereas “Density 2” (D2) is the second highest weight and “Density 3” (D3) is the 
lowest weight. “Mixture” was obtained by summing the geometric means of each density distribution 
weighted by their density in the mixture model. The geometric mean was used for all receptor 
distributions (18,550 VEGFR1/Mixture, 1,950 VEGFR2/Mixture, 13,000 VEGFR1/D1, 1,450 
VEGFR2/D1, 69,500 VEGFR1/D2, 1,100 VEGFR2/D2, 1,200 VEGFR1/D3, 10,900 VEGFR2/D3). The 
control reflects previously published VEGFR1 and VEGFR2 levels (1,100 VEGFR1/tEC and 700 
VEGFR2/tEC) [23]. 
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Figure 1.11: The insertion rate of VEGFR1 tunes the anti-angiogenic effect of anti-VEGF 
treatment. 
Sensitivity analysis of the insertion rate of VEGFR1 into the tEC membrane tunes the efficacy of anti-
VEGF treatment. This example examines “Density 2” at 3 weeks of tumor growth giving 69,500 
VEGFR1/tEC. The insertion rate using 69,500 VEGFR1/tEC is approximately 1e-14 s-1, where anti-
VEGF treatment provides a pro-angiogenic response. Decreasing the insertion rate allows for anti-VEGF 
treatment to provide an anti-angiogenic response. 
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Figure 1.12: Effect of tEC receptor levels on anti-VEGF treatment at 6 weeks of tumor growth. 
Free VEGF in the diseased tissue compartment in response to anti-VEGF treatment after updating (A) 
VEGFR1 alone, (B) VEGFR2 alone, and (C) both receptors on the tECs at 6 weeks of tumor growth. 
“Density 1” (D1) corresponds to the Gaussian with highest weight in the mixture model, “Density 2” (D2) 
is the second highest weight and “Density 3” (D3) is the lowest weight. “Mixture” was obtained by 
summing the geometric means of each density distribution weighted by their density in the mixture 
model. The geometric mean was used for all receptor distributions (1,500 VEGFR1/Mixture, 1,100 
VEGFR2/Mixture, 600 VEGFR1/D1, 600 VEGFR2/D1, 1,700 VEGFR1/D2, 2,400 VEGFR2/D2, 12,250 
VEGFR1/D3, 600 VEGFR2/D3). The control reflects previously published VEGFR1 and VEGFR2 levels 
(1,100 VEGFR1/tEC and 700 VEGFR2/tEC) [23].   
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Table 1.1: Bootstrapping the low bin search method. 
Sample 
Size 
Complete 
Data Set 
1,000 
Max 
1,000 
Min 
5,000 
Max 
5,000 
Min 
10,000 
Max 
10,000 
Min 
Sampling 31.28 31.29 32.92 31.15 31.80 31.18 31.68 
Add 20% 31.28 31.20 31.38 31.20 31.40 31.21 31.38 
Bootstrapping by either (1) running low bin search on random samples of the data set or (2) increasing 
randomly selected samples in value by 20% using the VEGFR1 data from C57BL/6 mice. Values in the 
table indicate free VEGF (pM) in the diseased compartment 3 weeks after anti-VEGF treatment using the 
maximum and minimum geometric means obtained from 100 trials of each sample size shown in Figure 
1.2. Free VEGF using the geometric mean obtained from the complete data set is shown to compare how 
much bootstrapping perturbs the system output.   
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Table 1.2: Representative receptor levels and best fit parameters for each receptor distribution.  
Receptor 
Type 
Geometric 
Mean 
Arithmetic 
Mean 
Mode Median Weibull 
Parameters 
Gamma 
Parameters 
Lognormal 
Parameters 
H:VEGFR1 2,530 3,000 2,720 2,500 1.67; 3,360 3.16; 940 7.83; 0.57 
H:VEGFR2 5,260 6,950 11,400 5,350 1.43; 7,690 1.94; 3,570 8.57; 0.78 
H:VEGFR3 3,380 4,680 1,980 3,150 1.28; 5,070 1.69; 2,750 8.13; 0.80 
H:NRP1 74,570 81,200 87,260 77,370 2.65; 91,330 6.03; 13,460 11.22; 0.44 
C:VEGFR1 2,100 2,970 1,820 2,050 1.24; 3,200 1.60; 1,860 7.65; 0.84 
C:VEGFR2 1,540 2,180 2,860 1,510 1.24; 2,350 1.60; 1,360 7.34; 0.84 
B:VEGFR1 2,700 3,850 1,700 2,650 1.20; 4,130 1.56; 2,470 7.90; 0.84 
B:VEGFR2 1,900 2,690 1,200 1,800 1.23; 2,900 1.60; 1,680 7.55; 0.83 
The number of receptors per cell given by the geometric mean, arithmetic mean, mode, and median of the 
data sets after applying low bin search. Data was used from HUVECs, C57BL/6 mice, and BALB/c mice, 
as indicated in the “Receptor Type” column by H, C, and B, respectively. The best fit parameters of the 
Weibull and Gamma distributions are given as ( ; )k  , and the best fit parameters of the lognormal 
distribution is given as ( ; )  . In vitro HUVEC data was quantified with flow cytometry measurements 
as described in [10], while the mice data was quantified with flow cytometry on primary mouse 
endothelial cells freshly isolated from gastrocnemius and tibialis anterior of male and female 8-10 week 
old mice [11]. 
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Table 1.3: Representative receptor levels obtained from each tri-modal Gaussian mixture model. 
Whole Cell 
Values 
Week 3 
tEC R1 
tEC R2 Tumor 
R1 
Tumor 
R2 
Week 6 
tEC R1 
tEC 
R2 
Tumor 
R1 
Tumor 
R2 
M:Geometric 18,550 1,950 3,300 2,200 1,500 1,100 2,800 1,250 
M:Mode 19,450 2,000 3,400 2,300 1,500 1,100 2,850 1,300 
D1:Geometric 13,000 1,450 2,900 1,500 600 600 3,150 950 
D1:Mode 13,700 1,400 3,000 1,500 600 650 3,300 1,000 
D2:Geometric 69,500 1,100 1,200 3,750 1,700 2,400 650 1,500 
D2:Mode 72,450 1,050 1,250 3,950 1,600 2,300 650 1,500 
D3:Geometric 1,200 10,900 13,250 14,950 12,250 600 8,500 2,300 
D3:Mode 1,150 11,000 13,500 16,800 13,150 600 8,550 2,300 
The geometric mean, arithmetic mean, and mode of the mixture model and the three Gaussian 
distributions that make up the mixture model for all cell types. “Density 1”, D1, corresponds to the 
Gaussian with highest weight in the mixture model M, whereas “Density 2”, D2, is the second highest 
weight and “Density 3”, D3, is the lowest weight. The mixture was obtained by summing the geometric 
means of each density distribution weighted by their density in the mixture model. Tumor cell and tEC 
receptor levels were quantified using flow cytometry on MDA-MB-231 xenografts, as previously 
described [13]. 
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CHAPTER 2 
HEMODYNAMIC ANALYSIS IN AN IDEALIZED ARTERY TREE: DIFFERENCES IN WALL 
SHEAR STRESS BETWEEN NEWTONIAN AND NON-NEWTONIAN BLOOD MODELS2 
 
2.1 Introduction 
Coronary artery disease causes 1 of every 6 deaths in America and can result from inadequate 
blood supply to cardiac muscles [77]. Similarly, occlusive vascular diseases and disorders such as 
arteriosclerosis, dementia, stroke, and coronary artery disease can develop as a result of abnormal blood 
flow [78, 79]. It remains challenging to identify pre-symptomatic patients who are at high risk of 
developing vascular occlusions [80]. Therefore, to better develop preventive techniques against 
hemodynamic dependent diseases, novel risk estimation techniques are necessary [81]. Hemodynamic 
modeling is one such preventive technique that can be utilized to predict disease risk. 
Hemodynamic simulations have been performed using patient-specific geometries 
reconstructed from imaging data [82, 83]. Patient-specific geometries capture anatomical complexity 
observed in physiology, offering promising approaches to advance personalized medicine in clinical 
assessment and diagnosis. Patient-specific studies have analyzed hemodynamic forces in aneurysms 
[84, 85], ventricular assist devices [86], and in the heart and aorta [87, 88]. Despite patient-specific 
studies such as these, the ability of the biofluid mechanics community to apply new methods to study, 
recreate, and validate patient-specific geometries has been severely limited. This problem arises 
because patient-specific geometries are not easily shared due to the containment of patient information.  
 
2This work has been previously published by the degree candidate. 
Citation information: Weddell JC, Kwack J, Imoukhuede PI, Masud A (2015) Hemodynamic Analysis in 
an Idealized Artery Tree: Differences in Wall Shear Stress between Newtonian and Non-Newtonian 
Blood Models. PLoS ONE 10(4): e0124575. doi:10.1371/journal.pone.0124575 
Copyright: © 2015 Weddell et al. This is an open access article distributed under the terms of the Creative 
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any 
medium, provided the original author and source are credited 
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To circumvent this problem, we present a biologically relevant idealized femoral artery tree geometry 
for numerical method verification. This test geometry will allow researchers to ensure that 
physiologically relevant numerical simulations are obtained before progressing into patient-specific 
geometries. 
Hemodynamic simulations have advanced the understanding of atherosclerotic lesion 
development and rupture and developed techniques to prevent these processes. Such studies have 
revealed that atherosclerotic lesion formation via low density lipoprotein accumulation preferentially 
occurs in arterial regions exhibiting low wall shear stress (WSS) [89-91]. Others have correlated low 
density lipoprotein accumulation with decreased WSS within arteries exhibiting increases in diameter 
[92-94]. Numerical simulations have revealed an increased atherosclerotic lesion rupture risk for 
lesions experiencing high WSS magnitudes in both patient-specific [95-97] and simplified geometries 
[98, 99]. Computer models have provided insight into preventing atherosclerotic lesion development 
by showing that the deposition of systemically injected nanoparticles into atherosclerotic lesions is 
highly dependent on the spatio-temporal WSS across these lesions [100-102]. While these studies have 
resulted in better insight into atherosclerotic lesion development and rupture, the dependency of WSS 
magnitude distributions across atherosclerotic lesions to the shear-rate dependent viscosity of blood is 
not well defined. We seek to uncover this relationship of WSS and blood viscosity using advanced 
computer models under both healthy and atherosclerotic conditions.   
Blood exhibits a range of viscosities dependent on the multiple cell types such as erythrocytes, 
leukocytes, and thrombocytes it contains. Blood viscoelastic characteristics are manifested via time-
dependent strains in response to stress, primarily due to viscoelastic membrane deformation of 
erythrocytes [103-105]. Viscous stress of blood is also shear-rate dependent and undergoes shear-
thinning, a decrease in viscosity with increasing shear-rate, primarily caused by transformation in 
microscopic rouleaux (stacks of erythrocytes) structures [106-108]. Various constitutive models of 
blood have been developed to capture this shear-rate dependency [109, 110]. Some commonly used 
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non-Newtonian models for blood are the Power-Law, Casson, Herschel-Bulkley, and Carreau-Yasuda 
models [111, 112]. The Power-Law model displays a linear response between viscosity and shear-rate 
on the log-log scale that is not seen in experimental blood viscosity measurements [111]. While the 
Casson and Herschel-Bulkley models provide good fits to experimental viscosity measurements at 
intermediate to high shear-rates, they fail to accurately capture blood viscosity at lower shear-rates 
[112]. Others and we have shown previously that the model choice does lead to differences in 
hemodynamic results including velocity and wall shear stress profiles [111, 113, 114]. Due to the 
dependency of flow predictions to the model employed, we chose to use the Carreau-Yasuda model 
here [115] as it more accurately fits empirically measured blood viscosity than these other non-
Newtonian models [116, 117] (Fig. 2.1). Viscosity as a function of shear-rate given by the Carreau-
Yasuda model is as follows: 
( 1)/
0
( )(1 ( ) ) n aa                                 (2.1) 
where   is the viscosity,   is the shear rate,   is the viscosity at infinite shear-rate, 0  is the 
viscosity at zero shear-rate, and  , a , and n  are material coefficients ( =1.902 s , a =1.25, n
=0.22). For blood,   = 0.00345 Pa s , 0  = 0.056 Pa s , and blood density is 1060 kg/m
3. 
Henceforth, the Carreau-Yasuda model is referred to as the shear-rate dependent fluid (SDF) model. 
Previous numerical simulations published in the literature have compared WSS between 
Newtonian and non-Newtonian models in coronary and femoral bypasses [118], curved artery models 
[98], 2-dimensional atherosclerosis [99], and patient-specific right coronary arteries [119]. While these 
studies have presented differences between Newtonian and non-Newtonian WSS, it remains unclear 
whether these differences are significant in a biological context, such as in determining atherosclerotic 
lesion growth rates. We attribute this deficiency to the lack of simple test geometries that would allow 
in-depth study of fundamental differences between Newtonian and non-Newtonian models to be 
observed in a biologically relevant context. The idealized femoral artery tree presented here is aimed 
to serve a benchmark problem to reveal these fundamental differences. 
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This paper also explores whether the Newtonian assumption of blood can accurately capture 
the physics of blood flow or if non-Newtonian models are necessary. To address this question, we 
quantitatively compare blood velocity, pressure, and WSS between the Newtonian and SDF models 
first in an idealized context and then in a biologically relevant context. Specifically, we compare 
Newtonian and SDF models using the lid-driven cavity flow problem, described by Ghia et al [120], 
as this is a benchmark problem with well-established solutions published in the literature (see 
Supporting Information). We verify our stabilized finite element method employing the lid-driven 
cavity problem, as well as in a biologically relevant context using the idealized single artery bifurcation 
presented by Chung [121]. We present an idealized femoral artery tree as a biologically relevant test 
geometry and use it to compare the Newtonian and SDF models under both healthy and atherosclerotic 
conditions.  
 
2.2 Materials and Methods 
A stabilized finite element method for shear-rate dependent fluids. Stabilized finite element 
methods for non-Newtonian biological fluids were presented in Masud and Kwack [109, 111, 122-
123]. These works are extensions of stabilized formulations for the Navier-Stokes equations by Masud 
and coworkers in [124-126]. Viscoelastic characteristics of blood at low shear-rates are markedly 
different from those at higher shear-rates and have the propensity to cause blood coagulation. 
Consequently, there has been tremendous interest in developing high fidelity numerical methods with 
enhanced stability properties [121, 123]. Specifically, the viscosity of blood varies substantially in the 
intermediate range of shear-rates that are typically encountered in human vasculature (Fig. 2.1). To 
address this issue, a stabilized formulation for shear-rate dependent blood flow was developed in [109, 
111] and extended to higher-order 3-dimensional elements in [122]. These studies [109, 111, 122-126] 
describe the complete formulations of the numerical method employed in this study.  
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To keep the discussion self-contained, we briefly describe the underlying method and the 
procedure. First, the desired geometry is discretized into a finite element mesh, and then stabilized 
finite element method for shear-rate dependent non-Newtonian fluids is employed for numerical 
simulations. The non-Newtonian viscous stress σv is defined as follows: 
   2v  σ ε v      (2.2) 
where γ is the shear-rate,     is the shear-rate dependent viscosity, and  ε v  is the rate-of-
deformation tensor. The fluid flow is governed by the incompressible momentum balance equations 
where the shear-rate dependent viscous stress is fully embedded: 
 , vt p     v v v σ v f         (2.3) 
0  v       (2.4) 
Equations (2.3) and (2.4) are the momentum-balance and incompressibility equations respectively, 
where  is the density, v is the velocity field, ,tv is the time derivative of the velocity, p is the pressure 
field, and f is the body force. 
Under suitable assumptions [109, 111, 122] the velocity field described by the incompressible 
momentum balance equations is decomposed into coarse- and fine-scales via the Variational Multiscale 
method [109, 122], leading to two sets of sub-problems that govern coarse- or resolvable scales and 
fine- or subgrid scales, respectively. The fine-scales are assumed to be represented by piecewise 
polynomials of sufficiently high order, continuous in space but discontinuous in time. It has been 
shown in our earlier works that the fine-scale problem is driven by the residual of the Euler-Lagrange 
equations for the coarse-scale. The fine-scale solutions thus approximate part of the physics that is 
beyond the resolution capacity of coarse-scale equations. These fine-scale solutions are then 
variationally embedded in the coarse-scale formulations, thereby resulting in the stabilized method. 
Solution of the stabilized form of the problem yields the coarse-scale solution on the given 
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discretization, yet it accounts for the fine-scale features in the solution via the variationally embedded 
fine-scale model represented by the stabilization terms. Thus, the resulting solution possesses enhanced 
accuracy and stability properties and is variationally consistent.  
This numerical method was implemented for linear and quadratic 3-dimensional elements and 
verified for stability and accuracy properties via numerical convergence-rate tests and steady-
state/transient benchmark problems [109, 122]. For completeness of discussion, the resulting nonlinear 
stabilized finite element formulation is presented: 
        
       
,, , , 2 ,
, , , ,
h
t p
q
  

     
    
w v w v v w ε v w
v χ τr w f w h
      (2.5) 
where w  the velocity field weighting functions,   is the element viscosity based on the mean value 
of the coarse-scale shear-rate, q  is the pressure field weighting functions, h  is the vector of the 
prescribed boundary tractions, and  is the boundary. The first five terms on the left-hand side of 
equation (2.5) represent the standard Galerkin form of the incompressible momentum balance 
equations in (2.2) and (2.3). The last term on the left-hand side represents the stabilization terms (χ,τr) 
that are derived via a local solution of the fine-scale problem that is then embedded in the coarse-scale 
formulation. Specifically, the various stabilization terms in (2.5) are defined as follows: 
 
c = r -Ñv ×w + Ñ×v( )w + v ×Ñw( )+h Ñ Ñ×w( )+Dw( )+Ñh × Ñ×w( )1+Ñw( )+Ñq    (2.6) 
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    , 2 2t p             r v v v ε v ε v f       (2.8) 
where eb  are bubble functions,   is the open bounded domain, which is discretized into non-
overlapping element domains e , and I  is the identity matrix.   is the weighting function for the 
stabilization term given in (2.5). τ is the stabilization tensor comprised of the operators of the 
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momentum balance equations acting on the fine-scale fields. It is numerically approximated via bubble 
functions and its gradients. r  is the residual of the Euler-Lagrange equations for the coarse-scales over 
the sum of element interiors. Consequently, the resulting method is residual based which is an 
important consideration in ensuring the consistency of the method. Furthermore, the additional 
stabilization terms play a critical role in obtaining stable solutions for the highly pulsatile flows in 
biofluid dynamics. 
The method employed here includes the fundamental features of classical stabilized methods 
(e.g., Streamline Upwind/Petrov-Galerkin (SUPG) method [127], or Galerkin/Least-Square (GLS) 
method [128]). In [124] it was shown that both SUPG and GLS are sub-classes of this method. In our 
earlier works, the enhanced stability of the method permitted us to use a first-order approximation for 
the nonlinear viscosity field without losing accuracy [111]. In [109] the method was extended to 3D 
employed hexahedral and tetrahedral elements with full description of nonlinear viscosity field. These 
methods [109, 111] come equipped with consistent mass/tangent tensors for nonlinear solution 
processes; therefore, they provide faster numerical convergence for large-scale transient simulations 
such as those presented here.  
Idealized femoral artery tree. The idealized femoral artery tree presented here contains rigid 
walls and straight cylindrical arteries and symmetric bifurcations. The mean flow rates [129-131] and 
diameters [130] were chosen as representative of an average adult femoral artery. The lengths of each 
artery were chosen such that blood flow would establish a full parabolic profile prior to reaching the 
subsequent bifurcation. The inlet velocity boundary condition has a parabolic profile along the parent 
artery as given by: 
 
2
max 2
(1 )
r
V V
R
                 (2.9) 
where V is the velocity at radial distance r  from the center line of the artery and R  is the artery radius. 
At the outlets of the idealized femoral artery tree, traction-free boundary condition is applied. The no-
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slip boundary condition was prescribed along all artery walls. Transient numerical simulations were 
performed across two inflow waveforms (two seconds), and numerical results presented in this paper 
were extracted from the second cycle to minimize effects of the initial flow condition. The radius of 
curvature (Rc) chosen will lead to pressure spikes at the bifurcation points of the idealized femoral 
artery tree. Using a larger Rc would distribute pressure more evenly across the bifurcation, however 
this smaller Rc was chosen for two reasons. First, it shows that our numerical method is stable and 
achieves convergence even for tougher numerical problems. Second, it is biologically relevant for 
stress to accumulate at artery bifurcations, which is the case for aneurysm development [132]. Grid 
convergence tests were performed on this artery to ensure that converged numerical results were 
obtained with mesh refinement (Fig. A.6). Numerical parameters used in the simulations on the 
idealized femoral artery tree, as well as other geometric configurations are also provided (Table A.2).  
Atherosclerosis simulations. Atherosclerotic lesions were added to the idealized femoral artery 
tree in one of two regions: within the parent artery or within the first bifurcation. Atherosclerotic lesions 
within the parent artery were numerically modeled for three different degrees of blocking: namely, 
25%, 50%, and 75% of the parent artery. Lesions within the first bifurcation blocked 35%, 50%, or 
72% of the daughter artery.  
Software. All geometries were developed in Autodesk Inventor and meshes were created 
using Abaqus/CAE. Atherosclerosis was modeled as a rigid wall with no slip conditions. Numerical 
tests were carried out with our in-house code that is based on the method presented here. Post-
processing and visualization of numerical data was carried out with Paraview. 
 
2.3 Results 
Idealized Bifurcating Artery Geometries. Our numerical method shows excellent agreement 
with the idealized single bifurcating artery simulations by Chung (Fig. 2.2A) [121]. For this 
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verification study, the Newtonian model was employed with viscosity = 0.00345 Pa/s, density = 1050 
kg/m3, and Re = 505. Pressure along the center of the parent artery from the inlet to the apex was 
compared for the verification (Fig. 2.2B). 
Velocity profiles throughout the idealized femoral artery tree. To investigate hemodynamic 
forces within a more relevant physiology, we developed an idealized femoral artery tree (Fig. 2.3A). 
Three time points were chosen as the comparison points between models, as defined by TA, TB, TC 
(Fig. 2.3B). A sample inflow velocity waveform at TA is given (Fig. 2.3C). Velocity contours at TB 
were extracted in daughter arteries immediately following the first and second bifurcation (Fig. 
2.4A). The Newtonian model requires longer artery distance to establish a parabolic profile following 
the first (Fig. 2.4B) and second bifurcations (Fig. 2.4C) than the SDF model. Additionally, the 
Newtonian model gives lower velocities near the artery wall opposite the bifurcation point (Fig. 
2.4B-C). 
Velocity profiles across cross sections of the first and second bifurcations were extracted at 
TB (Fig. 2.5A). At the beginning of bifurcations the SDF velocity profiles exhibit a flatter peak than 
the Newtonian velocity profiles (Fig. 2.5B,23.5E). The SDF model undergoes less fluid reversal near 
the artery walls within the bifurcation than the Newtonian model (Fig. 2.5C-D, 2.5F-G). The SDF 
model peak velocity is also lower than the Newtonian peak velocity across every slice (Fig. 2.5B-G). 
For verification purposes, velocity profile slices at TA and TC are also given (Fig. A.7, A.8).  
Velocity streamlines show that at TA there is no noticeable difference in velocity between the 
two models at both the first (Fig. 2.6A) and second (Fig. 2.6C) bifurcations. At TB both models 
exhibit noticeable fluid reversal following the first bifurcation, but the SDF fluid reversal is less 
pronounced than the Newtonian fluid reversal (Fig. 2.6B). While the Newtonian model still exhibits 
fluid reversal within the second bifurcation, no fluid reversal is noticeable with the SDF model (Fig. 
2.6D). 
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Pressure drop across the idealized femoral artery tree. The SDF model always gives an 
equal or higher pressure drop (inlet pressure minus outlet pressure) across the idealized femoral 
artery tree than the Newtonian model (Fig. 2.7). The largest difference in pressure drop occurs at TB, 
where the Newtonian model gives 42.8% the pressure drop given by the SDF model (Table 2.1). The 
pressure drop given by the two models is most similar at TA, where the Newtonian model gives 
76.5% the pressure drop given by the SDF model (Table 2.1). 
Remark: In fluid dynamics governed by the incompressible momentum balance equations, 
the pressure field is computed up to an arbitrary constant. However the pressure drop computed by 
the momentum balance equations is accurate. In engineering systems where the value of the pressure 
field is invariably known at some point in the domain, prescribing that known value as a boundary 
condition eliminates the arbitrary constant from the pressure field. In the present context of blood 
flow through arteries, a precise value of the pressure field to be applied as a pressure boundary 
condition is not readily available. Consequently, we have opted for traction-free boundary conditions 
on the outlet, making the average value of the outlet pressure equal to zero. It is important to note 
that even in this case the pressure drop between the inflow and outflow is accurately captured by the 
model. 
WSS across the idealized femoral artery tree. WSS contours show that at TA the SDF model 
gives noticeably higher WSS along both sets of daughter arteries than the Newtonian model (Fig. 
2.8A). WSS is computed by: 
( ) (( ) )WSS     n n n n        (2.10) 
where   is the stress tensor and n  is the surface normal vector. The difference between SDF and 
Newtonian WSS across the entire idealized femoral artery tree is qualitatively most noticeable at TB 
(Fig. 2.8B). At TC, there is a larger difference in WSS at the bifurcation points between the two 
models than at the other two time points (Fig. 2.8C). 
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The SDF model always gives higher WSS compared to the Newtonian model at the inflow, 
outflow, and outer bifurcation walls along the idealized femoral artery tree (Fig. 2.9). At the inflow 
wall, the Newtonian model gives a mean WSS of 0.24 Pa and the SDF model gives a mean WSS of 
0.32 Pa (Fig. 2.9P-1). At the wall opposite the first bifurcation, the Newtonian model gives a mean 
WSS of 0.06 Pa and the SDF model gives a mean WSS of 0.14 Pa (Fig. 2.9P-2). At the wall opposite 
the second bifurcation, the Newtonian model gives a mean WSS of 0.04 Pa and the SDF model gives 
a mean WSS of 0.12 Pa (Fig. 2.9P-3). At the outflow wall, the Newtonian model gives a mean WSS 
of 0.07 Pa and the SDF model gives a mean WSS of 0.13 Pa (Fig. 2.9P-4). Thus, the mean WSS of 
the two models was most similar at the inflow wall and least similar at the wall opposite the second 
bifurcation. 
WSS along the wall opposite the first bifurcation was extracted as a function of spatial 
location and time (Fig. 2.10A). The difference in WSS between the two models (|SDFWSS – 
NewtonianWSS|) shows that the largest difference in WSS occurs at the start of the bifurcation (0.03 
arc length) at TB (0.5s) (Fig. 2.10B). Following the bifurcation, the WSS difference holds 
approximately constant at 0.02 Pa for every time and spatial location (Fig. 2.10B). 
Comparison of SDF and Newtonian models across an atherosclerotic artery. WSS given 
with the SDF model is higher than WSS with the Newtonian model for every degree of 
atherosclerosis simulated (Fig. 2.11). As the degree of atherosclerosis increases, WSS along the 
opposite wall also increases; the maximum WSS in parent artery atherosclerosis at TA with the SDF 
model is 0.60 Pa at 25% artery blockage, 1.28 Pa at 50% blockage, and 4.17 Pa at 75% blockage. 
Conversely, the Newtonian model gives 0.50 Pa at 25% artery blockage, 1.15 Pa at 50% blockage, 
and 3.25 Pa at 75% blockage. The maximum WSS in bifurcation atherosclerosis at TA with the SDF 
model is 0.89 Pa at 35% artery blockage, 0.93 Pa at 50% blockage, and 1.58 Pa at 72% blockage. 
Conversely, the Newtonian model gives 0.86 Pa at 35% artery blockage, 0.88 Pa at 50% blockage, 
and 1.33 Pa at 72% blockage.  
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2.4 Discussion 
We compared blood velocity, pressure, and WSS given by SDF and Newtonian models. We 
confirm that differences between models in these comparisons do not arise from numerical error by 
verifying our stabilized finite element method with the 2-dimensional lid-driven cavity flow problem 
and the idealized single bifurcating artery. Our numerical simulations show that the Newtonian velocity 
profiles scale linearly with cavity height and width dimensions, while the SDF velocity profiles scale 
nonlinearly. In the 3-dimensional lid-driven cavity flow, the SDF model gives equivalent or larger 
WSS and wall pressure than the Newtonian model across the entirety of the cavity walls. Within the 
idealized femoral artery tree, the SDF model gives lower peak blood velocities, yet higher pressure 
drops, than the Newtonian model. Our numerical simulations show that the Newtonian model exhibits 
less WSS than the SDF model at every time and spatial location along the idealized femoral artery tree 
under both healthy and atherosclerotic conditions. These differences are attributed solely to the 
difference in blood viscosity between the two models; the Newtonian blood viscosity is constant 
whereas the SDF blood viscosity is dependent on the blood shear-rate.  
Newtonian velocity profiles scale linearly with cavity size. The Newtonian model gives similar 
velocity profiles through the 2-dimensional cavity scaled at differential height and width dimensions, 
given that Re is held constant. Conversely, the SDF velocity profiles scale nonlinearly with cavity 
height and width. This occurs because cavity scaling alters shear-rate magnitude and distribution 
throughout the cavity, which does not affect Newtonian velocity profiles as the Newtonian viscosity is 
solely determined by Re. This result implies Newtonian velocity profiles through identical arteries at 
different scales will be identical, but this is not physiologically relevant due to the shear-rate dependent 
viscosity of blood. This physiological irrelevancy could alter the predicted distribution of flowing 
platelets throughout a blood vessel, which is controlled by the blood velocity profile and important in 
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wound healing and atherosclerotic lesion formation, [133]. Thus, numerical simulations using 
Newtonian blood models can provide inaccurate velocity profiles resulting in incorrect risk estimations 
of hemodynamic-dependent diseases.  
The Newtonian model gives higher peak velocities throughout the idealized femoral artery tree 
than the SDF model. Our numerical simulations show that the Newtonian peak velocity through the 
parent artery of the idealized femoral artery tree is 0.075 m/s greater than the SDF peak velocity. 
Physiologically relevant peak blood velocities are critical for risk estimation of scleroderma and 
systemic sclerosis development in response to abnormally low blood velocities [134]. Magnetic 
nanoparticles administered to disrupt atherosclerotic lesion formation are also highly dependent on 
peak blood velocities [135, 136]. Peak blood velocities provided by numerical simulations must be 
physiologically relevant in order to accurately estimate hemodynamic-dependent disease progression.  
The Newtonian model gives lower pressure drops across the idealized femoral artery tree than 
the SDF model. Our numerical simulations show that the pressure drop across the idealized femoral 
artery tree with the SDF model is approximately 2.3-fold higher than that with the Newtonian model. 
Also, the SDF pressure drop across the 3-dimensional cavity is approximately 5-fold higher than the 
Newtonian pressure drop. These differences are significant because abnormally low pressure drops 
occur over flow resistive arterial regions which have high likelihood of stenosis formation [137]. Thus, 
it is essential that numerical simulations provide physiologically relevant pressure maps to accurately 
predict hemodynamic-dependent disease progression. 
Comparison of numerically predicted WSS to empirical measurements. The Newtonian model 
gives a mean WSS of 0.24 Pa along the parent artery of the idealized femoral artery tree whereas the 
SDF model gives a mean WSS of 0.32 Pa. Due to the prescribed dimensions and inflow waveform, the 
parent artery corresponds to the common femoral artery. Ultrasound measurements found WSS in the 
common femoral artery to be 0.35 ± 0.03 Pa in one study [138] and 0.36 ± 0.02 Pa in another [139] 
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(mean ± standard error of the mean). Thus, WSS given by the SDF model matches well with empirical 
data, whereas WSS given by the Newtonian model does not match empirical data as effectively.  
The Newtonian model exhibits less WSS than the SDF model across the idealized femoral 
artery tree in disease-free physiology. This difference in WSS of 0.12 Pa between the Newtonian and 
SDF models in healthy physiology is significant and will result in differential predictions of 
physiological processes. For example, laminar flow chamber experiments correlate this difference with 
a 3-fold higher amount of monocytes adhering to endothelial cells predicted by the Newtonian model 
than the SDF model; monocyte adhesion to the vascular wall contributes to atherosclerotic lesion 
development and rupture [140]. This WSS difference between models is also significant for predicting 
growth of atherosclerotic lesions or aneurysms [141-144] and vascular remodeling through integrin, 
adhesion molecule, and ion channel mechanotransduction [145-147]. For example, atherosclerotic 
lesion growth studies measured that arteries experiencing 0.12 less WSS had an increased lesion 
growth of 0.05 mm over the course of a year [142]. Patch clamp experiments on endothelial cells 
measured a K+ current of approximately 21 pA when a WSS of 0.086 Pa was applied, versus a K+ 
current of approximately 5 pA when a WSS of 0.035 Pa was applied [147]. This 4-fold increase in K+ 
current given a WSS difference of 0.05 Pa indicates that the difference of 0.12 Pa between the two 
models will result in significantly different endothelial cell K+ current predictions. These studies 
coupled with our numerical simulations imply that physiologically relevant WSS in disease-free 
models is essential to accurately predict induction of hemodynamic-dependent diseases.  
The Newtonian model gives less WSS than the SDF model across the idealized femoral artery 
tree in atherosclerotic conditions. Our numerical simulations show that the SDF model gives up to 
1.09 Pa greater WSS than the Newtonian model across multiple degrees of atherosclerotic lesion 
progression in the idealized femoral artery tree. This difference is significant because the number of 
monocyte to endothelial cell adhesions, important to atherosclerotic lesion development and rupture, 
increased approximately 3-fold after decreasing WSS by 0.1 Pa (1 dyn/cm2) in laminar flow chamber 
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experiments [140]. Higher WSS also increases multimeric von Willebrand factor uncoiling, which is 
localized to injured vessel walls to adhere and activate platelets to facilitate clotting and wound healing 
[148-151]. Thus, physiologically relevant WSS provided by numerical simulations in atherosclerotic 
conditions is essential to properly assess risk of further atherosclerotic lesion progression. 
Limitations of idealized femoral artery tree numerical simulations. The idealized femoral 
artery tree consists of a rigid body, whereas arteries physiologically exhibit elastic properties. Previous 
studies have sought to determine the significance of compliant artery walls compared to rigid walls. 
Leung et al found a negligible difference of less than 1% in the peak WSS determined by the compliant 
and rigid wall models using patient-specific abdominal aortic aneurysm geometries [152]. However, 
Scotti et al found that in abdominal aortic aneurysms with varying wall thickness and asymmetry the 
rigid wall model underestimated WSS by up to 30.2% [153]. In atherosclerotic carotid arteries, Yang 
et al found that differences in maximum shear-stress between rigid and compliant artery wall models 
were significant within flow-stagnation regions, but insignificant within high shear-stress regions [95]. 
These discrepancies indicate a need to better understand under what circumstances compliant artery 
wall models are necessary. The idealized femoral artery tree can serve as a test bed for identifying the 
conditions under which a coupled blood-artery wall model would be necessary. 
Future directions. Our ability to numerically simulate transient blood flow can be applied to 
predict the efficacy of exercise regimes in preventing or treating diseases. For example, exercise is 
highly beneficial in the prevention of Type 2 diabetes [154, 155], but the type and rigor a diabetic 
patient should undergo is not well defined [156]. Exercise also remains the best intervention for 
peripheral artery disease through its induction of angiogenesis leading to an increased capillary density 
[157]. Numerical simulations could optimize exercise regimes for individual patients. However, 
properly optimized exercise regimes require accurate arterial wall properties. For example, exercise in 
healthy patients was found to be associated with a 50% decrease in pulmonary artery resistance but a 
30% increase in pulmonary artery compliance [158], indicating that artery resistance and compliance 
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are inversely correlated [159]. Age and sex can also be an important factor in artery wall properties, as 
women and patients under 50 years old were shown to have greater distensibility in pulmonary arteries 
[160]. These changes in artery wall properties are likely dependent in part on the increased cardiac 
output and artery pressures observed in exercise [161]. Thus, as our current numerical method is limited 
to modeling arterial walls as rigid bodies, extending this numerical method to account for arterial 
compliance and resistance changes is necessary to predict optimized exercise regimes. Hemodynamic 
models can also be applied towards developing and optimizing therapeutic approaches. For example, 
tumor blood flow can be constricted through rupturing microvessel with microbubbles [162], and 
numerical simulations could predict which microvessels should be targeted to most effectively starve 
tumors. Extending hemodynamic models to dynamically model physiological processes would provide 
additional insight into the process. For example, previous studies dynamically modeling sprouting 
angiogenesis revealed the dependency of molecular concentrations to blood flow [163, 23]. In all such 
studies, modeling hemodynamic forces and molecular interactions would provide a comprehensive 
overview of the biological process, allowing novel insight to be drawn or therapy optimizations to be 
developed. 
Concluding remarks. We present a 3-dimensional idealized femoral artery tree that can be used 
as a test bed for hemodynamic simulations through an easily reproducible geometry. We show that 
Newtonian models of blood yield lower WSS than the SDF model throughout the idealized femoral 
artery tree in both healthy and atherosclerotic conditions. Newtonian velocity profiles are shown to 
exhibit higher peak magnitudes than the SDF model within the healthy idealized femoral artery tree. 
Newtonian pressure is shown to be lower than SDF pressure within the 3-dimensional lid-driven cavity 
flow and the idealized femoral artery tree. Additionally, Newtonian velocity profiles scale linearly with 
the 2-dimensional height and width, whereas SDF velocity profiles scale nonlinearly. These differences 
are attributed to the non-Newtonian constitutive relation in the SDF model that is based on the 
empirically observed rheology of blood. We provide quantitative analysis of velocity, WSS, and 
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pressure throughout the idealized femoral artery tree that can be used as a benchmark for future studies. 
Future work will extend these ideas into patient-specific geometries or integrate non-Newtonian 
hemodynamics with molecular signaling to model atherosclerosis development.  
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2.6 Figures and Tables 
 
Figure 2.1: Viscosity of Newtonian and Carreau-Yasuda Constitutive Blood Models. The Carreau-
Yasuda model of blood shows the viscosity changing as a function of the shear-rate. The Newtonian 
model has constant viscosity at all shear-rates. 
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Figure 2.2: Numerical Method Verification via a 3-Dimensional Idealized Bifurcating Artery. (A) 
The 3-dimensional idealized bifurcating artery proposed by Chung [45] was used for verifying our 
method. The parent artery where the inflow is prescribed is 2 mm in diameter, 12.23 mm in length up to 
the bifurcation, and 13.95 mm in length to the bifurcation apex. The daughter arteries are both 1.2 mm in 
diameter and 12.72 mm in length from the bifurcation. The radius of curvature (Rc) is 0.1 mm, and the 
angle between the daughter artery walls is 60o. (B) Pressure was extracted along the center of the parent 
artery from the inflow to the apex of the bifurcation.  
 
 
 
 
61 
 
 
Figure 2.3: 3-Dimensional Idealized Femoral Artery Tree and Inflow Conditions. (A) Dimensions of 
the idealized femoral artery tree. The bifurcations are defined by the circled numbers, with the first 
bifurcation defined as the 9 mm artery bifurcating into 8.55 mm arteries and the second bifurcation 
defined as an 8.55 mm artery bifurcating into 8.1 mm arteries. In both bifurcations, centerline to 
centerline of the daughter arteries = 60o and the Rc = 2.25 mm. Dimensions for only one side of the 
idealized femoral artery tree are shown due to symmetry. (B) The inflow velocity waveform applied at the 
geometric center of the parent artery. Marked peaks on the inflow velocity waveform are time points 
where comparisons of the two models are drawn. (C) Example inlet boundary condition across the parent 
artery at TA. X-axis is shown as squared distance from the vessel center (r) over the squared vessel radius 
(R). The origin (0,0,0) of the idealized femoral artery tree is defined as the geometric center of the parent 
artery, and all spatial locations given for this geometry are based on this origin in Cartesian coordinates. 
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Figure 2.4: Daughter Artery Velocity Profiles. Daughter artery velocity profiles immediately following 
the idealized femoral artery tree bifurcations at TB. (A) Locations along the idealized femoral artery tree 
where the contours were extracted. Velocity profiles in daughter arteries following (B) the first 
bifurcation and (C) the second bifurcation. Artery walls adjacent to bifurcations are portrayed as the top 
wall, and artery walls opposite bifurcations are portrayed as the bottom wall. Velocity slices were 
extracted from planes intersecting the idealized femoral artery tree. The (x,y,z) coordinates in mm are 
given for each velocity slice indicates the origin of the plane, which were oriented perpendicular to the 
normal vectors ( n ) given for each daughter artery. 
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Figure 2.5: Velocity Profiles within the Idealized Femoral Artery Tree Bifurcations at TB. (A) 
Velocity profiles plotted over the cross sections shown at TB. Velocity slices across first bifurcation were 
extracted at (B) the bifurcation start, (C) bifurcation midpoint, and (D) the bifurcation apex. Velocity 
slices were extracted at respective locations (E-G) across the second bifurcation. X-axis is shown as 
squared distance from the vessel center (r) over the squared vessel radius (R). For slices within the 
bifurcations (C, D, F, G) the vessel is not cylindrical, so R is chosen as half the wall to wall length. The 
solid black line is the SDF velocity profile and the dashed blue line is the Newtonian velocity profile. 
Velocity profiles were extracted from slices originated at the (x,y,z) coordinates in mm given, and slices 
were oriented perpendicular to the normal vectors ( n ) given for each bifurcation. 
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Figure 2.6: Velocity Streamlines through the Idealized Femoral Artery Tree Bifurcations. Velocity 
streamlines through the idealized femoral artery tree bifurcations for both models. (A) The first 
bifurcation at TA, (B) the first bifurcation at TB, (C) the second bifurcation at TA, and (D) the second 
bifurcation at TB. Due to symmetry, only one half of the idealized femoral artery tree is shown. The left 
half is the Newtonian model and the right half is the SDF model, separated across the black line. 
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Figure 2.7: The Pressure Drop Across the Idealized Femoral Artery Tree. The pressure drop (Pinflow – 
Poutflow) across the idealized femoral artery tree given by both models across two inflow waveforms. Due 
to symmetry, the pressure at all four outlets is identical, and thus any outlet artery can be chosen. 
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Figure 2.8: WSS Contours across the Idealized Femoral Artery Tree. WSS contours at instantaneous 
time points (A) TA, (B) TB, and (C) TC the idealized femoral artery tree. Due to symmetry, only one half 
of the idealized femoral artery tree is shown for each model, where the left half is the Newtonian model 
and the right half is the SDF model, separated across the black line.  
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Figure 2.9: WSS Versus Time Across the Idealized Femoral Artery Tree. WSS versus time at 
different spatial locations on the idealized femoral artery tree given by the (x,y,z) coordinates in mm. 
WSS is shown at the inflow wall (P-1), the wall opposite the first bifurcation (P-2), the wall opposite the 
second bifurcation (P-3), and the outflow wall (P-4). The solid black line is the SDF WSS and the blue 
dashed line is the Newtonian WSS.  
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Figure 2.10: WSS Across the Wall Opposite the First Bifurcation Versus Time and Spatial 
Location. (A) WSS was extracted along the wall opposite the first bifurcation shown by the black line. 
The (x,y,z) coordinates in mm are given for the three points shown. (B) The WSS magnitude difference 
between the two models (|SDFWSS – NewtonianWSS|) versus time and spatial location. Spatial location is 
given as arc length distance, where arc length of zero corresponds to the lowest spatial location along the 
artery wall. 
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Figure 2.11: WSS at Varying Degrees of Atherosclerosis. Atherosclerotic lesions of varying degrees 
were induced in the idealized femoral artery tree at the inflow artery or at the first bifurcation. The (x,y,z) 
coordinates in mm show were the atherosclerotic lesion endpoints were prescribed. WSS from the SDF 
and Newtonian models were extracted along the wall opposite the plaque and plotted at TA, TB, and TC. 
The x-axis indicates location along the wall, where zero corresponds to the lowest y-coordinate of the 
plaque and one as the highest y-coordinate. 
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Table 2.1: The pressure drop across the idealized femoral artery tree.  
 Time TA Time TB Time TC 
Newtonian (Pa) 42.26 8.42 21.39 
SDF (Pa) 55.25 19.66 33.29 
Percent (NSE/SDF) 76.5 42.8 64.2 
The pressure drop (Pinflow – Poutflow) given by the two models at TA, TB, and TC.  The percent is the pressure 
drop given by the Newtonian model divided by the pressure drop given by the SDF model.   
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APPENDIX A: SUPPLEMENTARY FIGURES AND TABLES 
 
Figure A.1: Statistical distribution fits to ex vivo receptor populations.  
Cell-by-cell analysis of VEGFR1/2 distributions from C57BL/6 (A-B) and BALB/c (C-D) mice. Each 
distribution was fit to Weibull (generalized extreme value distribution), Gamma (maximum entropy 
probability distribution), and lognormal (logarithm is normally distributed) probability density functions. 
The parameters for the best fit distributions are given in Table 1.2. 
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Figure A.2: Receptor level effect on free VEGF levels in the healthy body model. 
Comparison of adding ex vivo or in vitro receptor levels in the healthy body model. VEGF concentration 
was initialized at 0 pM and simulated to steady state. The geometric mean (2,100 VEGFR1/C57, 1,540 
VEGFR2/C57, 2,700 VEGFR1/BAL, 1,900 VEGFR2/BAL, 2,530 VEGFR1/HUVEC, 5,260 
VEGFR2/HUVEC) and mode (1,820 VEGFR1/C57, 2,860 VEGFR2/C57, 1,700 VEGFR1/BAL, 1,200 
VEGFR2/BAL, 2,720 VEGFR1/HUVEC, 11,400 VEGFR2/HUVEC) of the distributions were used. 
(A,D) Free VEGF response in updating VEGFR1 alone, (B,E) updating VEGFR2 alone, and (C,F) 
updating both simultaneously. The control reflects previously published VEGFR1 and VEGFR2 levels 
(1,100 VEGFR1/cell and 700 VEGFR2/cell) [23]. 
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Figure A.3: Receptor level effect on free VEGF levels in the tumor model. 
Comparison of adding ex vivo or in vitro receptor levels in the tumor model. An optimized anti-VEGF 
agent is added at t = 0 and the VEGF concentration response is simulated to 3 weeks after injection. The 
geometric mean (2,100 VEGFR1/C57, 1,540 VEGFR2/C57, 2,700 VEGFR1/BAL, 1,900 VEGFR2/BAL, 
2,530 VEGFR1/HUVEC, 5,260 VEGFR2/HUVEC) and mode (1,820 VEGFR1/C57, 2,860 
VEGFR2/C57, 1,700 VEGFR1/BAL, 1,200 VEGFR2/BAL, 2,720 VEGFR1/HUVEC, 11,400 
VEGFR2/HUVEC) of the distributions were used. (A-C) Free VEGF response in updating VEGFR1 
alone, (D-F) updating VEGFR2 alone, and (G-I) updating both simultaneously. The control reflects 
previously published VEGFR1 and VEGFR2 levels (1,100 VEGFR1/cell and 700 VEGFR2/cell) [23]. 
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Figure A.4: Effect of tumor cell receptor levels on anti-VEGF treatment at 3 weeks of tumor 
growth. 
Free VEGF in the normal tissue, blood, and diseased tissue compartments in response to anti-VEGF 
treatment after updating (A-C) VEGFR1 alone, (D-F) VEGFR2 alone, and (G-I) both receptors on the 
tumor cells at 3 weeks of tumor growth. “Density 1” (D1) corresponds to the Gaussian with highest 
weight in the mixture model, “Density 2” (D2) is the second highest weight, and “Density 3” (D3) is the 
lowest weight. “Mixture” was obtained by summing the geometric means of each density distribution 
weighted by their density in the mixture model. The geometric mean was used for all receptor 
distributions (3,300 VEGFR1/Mixture, 2,200 VEGFR2/Mixture, 2,900 VEGFR1/D1, 1,500 VEGFR2/D1, 
1,200 VEGFR1/D2, 3,750 VEGFR2/D2, 13,250 VEGFR1/D3, 14,950 VEGFR2/D3). The control reflects 
previously published VEGFR1 and VEGFR2 levels (1,100 VEGFR1/cell and 700 VEGFR2/cell) [23]. 
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Figure A.5: Effect of tumor cell receptor levels on anti-VEGF treatment at 6 weeks of tumor 
growth. 
Free VEGF in the normal tissue, blood, and diseased tissue compartments in response to anti-VEGF 
treatment after updating (A-C) VEGFR1 alone, (D-F) VEGFR2 alone, and (G-I) both receptors on the 
tumor cells at 6 weeks of tumor growth. “Density 1” (D1) corresponds to the Gaussian with highest 
weight in the mixture model, “Density 2” (D2) is the second highest weight, and “Density 3” (D3) is the 
lowest weight. “Mixture” was obtained by summing the geometric means of each density distribution 
weighted by their density in the mixture model. The geometric mean was used for all receptor 
distributions (2,800 VEGFR1/Mixture, 1,250 VEGFR2/Mixture, 3,150 VEGFR1/D1, 950 VEGFR2/D1, 
650 VEGFR1/D2, 1,500 VEGFR2/D2, 8,500 VEGFR1/D3, 2,300 VEGFR2/D3). The control reflects 
previously published VEGFR1 and VEGFR2 levels (1,100 VEGFR1/cell and 700 VEGFR2/cell) [23]. 
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Figure A.6: Grid convergence tests on the idealized femoral artery tree at Re = 550. Grid 
convergence tests were performed using (A) the velocity profile across the first bifurcation (slice at y = 
54.2 mm), (B) the velocity profile across the second bifurcation (slice at y = 160 mm after rotating the 
idealized femoral artery tree by 30o in the z-direction), and (C) WSS at the four points along the idealized 
femoral artery tree as given in Figure 2.9. Graph inserts are a zoomed in comparison between the meshes 
near the center of the bifurcation. Five meshes were used for the convergence test, with the first figure 
legend indicating the approximate number of elements each mesh contains. The mesh used for 
simulations in this study contains approximately 173,000 elements. Note that grid convergence tests were 
not performed for the 2-dimensional cavity or the single bifurcating artery as validations were provided 
for those geometries. For the 3-dimensional cavity geometry, our group provided convergence tests in a 
previous manuscript [109]. 
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Figure A.7: Velocity Profiles within the Idealized Femoral Artery Tree Bifurcations at TA. (A) 
Velocity profiles plotted over the cross sections shown at TA. Velocity slices across first bifurcation were 
extracted at (B) the bifurcation start, (C) bifurcation midpoint, and (D) the bifurcation apex. Velocity 
slices were extracted at respective locations (E-G) across the second bifurcation. X-axis is shown as 
squared distance from the vessel center (r) over the squared vessel radius (R). For slices within the 
bifurcations (C, D, F, G) the vessel is not cylindrical, so R is chosen as half the wall to wall length. The 
solid black line is the SDF velocity profile and the dashed blue line is the Newtonian velocity profile.  
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Figure A.8: Velocity Profiles within the Idealized Femoral Artery Tree Bifurcations at TC. (A) 
Velocity profiles plotted over the cross sections shown at TC. Velocity slices across first bifurcation were 
extracted at (B) the bifurcation start, (C) bifurcation midpoint, and (D) the bifurcation apex. Velocity 
slices were extracted at respective locations (E-G) across the second bifurcation. X-axis is shown as 
squared distance from the vessel center (r) over the squared vessel radius (R). For slices within the 
bifurcations (C, D, F, G) the vessel is not cylindrical, so R is chosen as half the wall to wall length. The 
solid black line is the SDF velocity profile and the dashed blue line is the Newtonian velocity profile.  
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Table A.1: Percent of each data set defined as outliers. 
 Low Bin Search 3 STD Removed 
Untreated: 
VEGFR1 0.18 0.12 
VEGFR2 0.25 0.13 
VEGFR3 0.24 0.17 
NRP1 0.18 0.79 
VEGF-A: 
VEGFR1 0.52 0.1 
VEGFR2 0.08 0.04 
VEGFR3 8.32 0.73 
NRP1 0.12 0.67 
VEGF-C: 
VEGFR1 0.23 0.4 
VEGFR2 0.25 0.1 
VEGFR3 0.24 0.04 
NRP1 0.17 0.2 
Percent of each complete raw data set defined as outliers, where outliers are defined using low bin search 
or by removing all data 3 standard deviations (STD) above the mean. The largest difference in percent 
defined as outliers between low bin search and 3 STD is 7.59%. 
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Table A.2: Numerical parameters for simulations of each geometry used in this study.  
Geometry Element 
type 
Number of 
elements 
Number of 
nodes 
Time 
step 
size (s) 
Number 
of time 
steps 
Initial 
velocity 
(m/s) 
Re 
simulated 
2-dimensional 
cavity 
HEX8 25,600 51,842 50 20 3.25 x 
10-5 
10,000 
3-dimensional 
cavity 
HEX8 262,144 274,625 1 100 3.25 x 
10-5 
1,000 
Single 
bifurcating 
artery 
TET10 21,802 33,883 5 195 1.68 x 
10-3 
505 
Idealized 
femoral artery 
tree 
TET10 173,419 264,564 0.01 200 1.60 x 
10-1 
550 
The element type used was either the 8-node hexahedral (HEX8) or the 10-node tetrahedral (TET10) 
element. Note that the 2-dimensional cavity was created as a 3-dimensional geometry using HEX8 
elements with the cavity thickness (z-dimension) being 20% of the height and width (0.05 m for the full 
size cavity). However, the z-directional velocity was held constant at zero to produce 2-dimensional 
physics from a 3-dimensional geometry. We conducted the 2-dimensional cavity simulations in this way 
because our numerical method provides greater stability and convergence rates for 3-dimensional element 
types. All geometries except for the idealized femoral artery tree were simulated at steady state, and thus, 
given the chosen initial velocity, the number of time steps taken were used to reach the desired Re. The 
idealized femoral artery tree was simulated transiently, and 200 time steps were chosen to simulate the 
time course of 2 seconds. The Re indicated for the idealized femoral artery tree is the mean Re through the 
parent artery over the inflow velocity waveform. 
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APPENDIX B: HEMODYNAMIC NUMERICAL METHOD VALIDATION 
B.1 Hemodynamic benchmark problem: lid-driven cavity flow 
2-dimensional Lid-Driven Cavity Flow Numerical Simulations. To ensure our hemodynamic 
numerical method provides accurate numerical results, we tested our method using the benchmark 
lid-driven cavity flow problem published by Ghia and colleagues [120]. The cavity has length and 
width dimensions of 1 m x 1 m (denoted full sized), and a tangential velocity was introduced across 
the top of the cavity in the positive x-direction (Fig. B.1). The Reynolds numbers (Re) is expressed 
as: 
VL
Re


        (B.1) 
where ρ is the fluid density, V is the driving velocity, 𝜇 is the fluid viscosity, and L is the cavity height. 
We extracted the x-component of the velocity (Vx) along the y-axis in the geometric center of e cavity 
across Re of 1,000; 5,000; and 10,000. 
Given the same Re, the Newtonian model gives similar velocity profiles through the 2-
dimensional cavity at different height and width scales, whereas the SDF gives notably different 
velocity profiles. The cavity was made to three sizes: (i) the full size cavity (1 m x 1 m), (ii) with height 
and width 10% of the full size (0.1 m x 0.1 m), and (iii) with height and width 1% of the full size (0.01 
m x 0.01 m). Simulations were performed using three Re for each cavity size (Re = 500; 5,000; and 
10,000), chosen as a representative range of Re seen in arterial blood flow [129].  
Remark: The Re is not constant throughout the cavity with the SDF model, due to the SDF 
viscosity being inconsistent across the cavity. Thus, for the sake of comparison with the Newtonian 
model, the same inflow velocity giving a desired Re with the Newtonian model was applied to SDF 
model simulations.  
The Newtonian velocity profiles are identical for each cavity size at every Re (Fig. B.2), 
whereas the SDF velocity profiles largely differ amongst the cavity sizes at low Re, but become more 
similar as the Re is increased (Fig. B.3). The spatial location of lowest magnitude Vx in the SDF 
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velocity profiles is noticeably shifted compared to the Newtonian model (Table B.1). Additionally, the 
lowest Vx magnitude increases at different rates with increasing Re for the two models. The Newtonian 
model gives a 23.7-fold increase in the lowest Vx magnitude from Re = 500 to Re = 10,000 whereas 
the SDF models gives a 28.9-fold increase in the full size cavity, a 39.1-fold increase in the 10% cavity, 
and a 30.7-fold increase in the 1% cavity (Table B.1). 
We note distinct kinks, points of rapid slope change, in the velocity profiles (Fig. B.2, B.3). 
The spatial location of these kinks given by the SDF model is noticeably different for the different 
cavity sizes (Table B.2). However, the kinks given by the SDF model converge to those of the 
Newtonian model as the cavity size is decreased or the Re is increased (Table B.2).  
3-dimensional Lid-Driven Cavity Flow Numerical Simulations. The benchmark 2-
dimensional lid-driven cavity problem was extended to three dimensions. Simulations were 
performed to investigate the third dimensions impact on velocity, pressure, and WSS given by the 
Newtonian and SDF models. The driving velocity was again applied across the top of the cavity in 
the positive x-direction.       
The SDF model gives a larger pressure drop across the 3-dimensional cavity than the 
Newtonian model. Pressure and Vx were extracted along a line parallel to the y-axis in the geometric 
middle of the cavity (Fig. B.4). The Newtonian model displays a more fully developed circular flow 
profile than the SDF model, and the lowest Vx magnitude is 1.15-fold larger in the Newtonian model. 
Pressure profiles reveal that the SDF model has a 2.87-fold larger pressure drop across the cavity than 
the Newtonian model (Table B.3).  
The SDF model exhibits an equal or higher WSS magnitude at every spatial location across the 
3-dimensional cavity compared to the Newtonian model (Fig. B.5). Along the center of the right cavity 
wall, the SDF model gives 7.3-fold larger WSS and 4.1-fold larger pressure than the Newtonian model 
at Re = 1,000. Exponential growth curve fits show that WSS and pressure increase more rapidly with 
the SDF model than the Newtonian model. 
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B.2 Figures and Tables 
 
Figure B.1: Numerical Method Verification with the 2-Dimensional Lid-Driven Cavity Flow 
Problem. Verification of our numerical method using simulations provided by Ghia in the 2-dimensional 
lid-driven cavity flow problem [120]. (A) Flow profile throughout the cavity from the Newtonian model 
at Re = 10,000. Vx was extracted along the white line in the geometric center of the cavity at (A) Re = 
1,000; (B) Re = 5,000; and (C) Re = 10,000. The bottom of the cavity is defined as y = 0 and the top as y 
= 1. 
 
 
 
96 
 
 
Figure B.2: Effect of Cavity Size and Re on Newtonian Velocity Profiles. Effect of the cavity size on 
the Newtonian velocity profiles across the geometric center of the 2-dimensional cavity at (A) Re = 500, 
(B) Re = 5,000, and (C) Re = 10,000. The full cavity size is 1m x 1m, the 10% size is 0.1 m x 0.1 m, and 
the 1% size is 0.01 m x 0.01 m. The y-coordinate of the smaller cavities are scaled up for visualization 
purposes.  
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Figure B.3: Effect of Cavity Size and Re on SDF Velocity Profiles. Effect of the cavity size on the SDF 
velocity profiles across the geometric center of the 2-dimensional cavity at (A) Re = 500, (B) Re = 5,000, 
and (C) Re = 10,000. The full cavity size is 1m x 1m, the 10% size is 0.1 m x 0.1 m, and the 1% size is 
0.01 m x 0.01 m. The y-coordinate of the smaller cavities are scaled up for visualization purposes.  
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Figure B.4: Pressure and Velocity Profiles in the 3-Dimensional Cavity. (A) The 3-dimensional cavity 
(1m x 1m x 1m) with inflow applied across the top of the cavity in the positive x-direction. (B) Pressure 
and (C) Vx profiles were extracted along the red line parallel to the y-axis shown. The bottom of the 
cavity is defined as y = 0 and the top of the cavity as y = 1. 
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Figure B.5: WSS and Wall Pressure along the 3-Dimensional Cavity. (A) WSS across the 3-
dimensional cavity for the SDF (left) and Newtonian (right) models. (B) The 3-dimensional cavity where 
(C) WSS and (D) wall pressure were extracted along the red line parallel to the y-axis and along the right 
wall. The bottom of the cavity is defined as y = 0 and the top of the cavity is y = 1. 
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Table B.1: The lowest Vx magnitude for the 2-dimensional cavity at different sizes.  
Cavity Type  Vx (mm/s) at  
Re = 500 
Vx (mm/s) at  
Re = 5,000 
Vx (mm/s) at  
Re = 10,000 
Newtonian -0.54 -6.50 -12.8 
SDF (Full) -0.33 -4.56 -9.55 
SDF (10%) -2.55 -38.5 -99.82 
SDF (1%) -41.52 -640.1 -1273.10 
The lowest Vx magnitude in mm/s along the geometric center of the 2-dimensional cavity for the 
Newtonian and SDF models. The bottom of the cavity is defined as y = 0 m and the top as y = 1 m. Only 
one cavity size is shown for the Newtonian model. 
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Table B.2: Spatial locations of kinks in Vx profiles in the 2-dimensional cavity at different sizes.  
Cavity Type Kink location (m) at  
Re = 500 
Kink location (m) 
at Re = 5,000 
Kink location (m) 
at Re = 10,00 
First Second First Second First Second 
Newtonian 0.26 0.89 0.08 0.95 0.06 0.97 
SDF (Full) 0.52 - 0.32 0.86 0.21 0.88 
SDF (10%) 0.54 - 0.11 0.94 0.06 0.95 
SDF (1%) 0.31    0.89 0.08 0.95 0.06 0.97 
The location of kinks in the Vx profile from the bottom of the cavity along the geometric center for the 
Newtonian and SDF models. Kinks are seperated by a semi-colon for that particular Re; if only one kink 
is present the second is labeled as “-“. Only one cavity size is shown for the Newtonian model. 
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Table B.3: Velocity and pressure differences between the two models in the 3-dimensional cavity.  
 Lowest Vx 
(mm/s) 
Lowest Vx 
Location (m) 
Lowest Pressure 
(mPa) 
Lowest Pressure 
Location (m) 
Highest  
Pressure (mPa) 
Newtonian -0.78 0.14 -0.31 0.50 0.00 
SDF -0.68 0.51 -0.79 0.82 0.10 
The lowest Vx magnitude and spatial location, lowest pressure magnitude and spatial location, and highest 
press magnitude for the Newtonian and SDF models across the geometric center of the 3-dimensional 
cavity at Re = 1,000. Spatial location are given in distance from the bottom of the cavity along the 
geometric center of the cavity. Highest pressure spatial location is always located at the top of the cavity, 
and is thus omitted. 
 
